Medical device for use in bodily lumens, for example an atrium

Information

  • Patent Grant
  • 11413091
  • Patent Number
    11,413,091
  • Date Filed
    Wednesday, October 13, 2021
    3 years ago
  • Date Issued
    Tuesday, August 16, 2022
    2 years ago
Abstract
A device positionable in a cavity of a bodily organ (e.g., a heart) may discriminate between fluid (e.g., blood) and non-fluid tissue (e.g., wall of heart) to provide information or a mapping indicative of a position and/or orientation of the device in the cavity. Discrimination may be based on flow, or some other characteristic, for example electrical permittivity or force. The device may selectively ablate portions of the non-fluid tissue based on the information or mapping. The device may detect characteristics (e.g., electrical potentials) indicative of whether ablation was successful. The device may include a plurality of transducers, intravascularly guided in an unexpanded configuration and positioned proximate the non-fluid tissue in an expanded configuration. Expansion mechanism may include helical member(s) or inflatable member(s).
Description
BACKGROUND
Field

This disclosure is generally related to percutaneous cardiac surgery, and more particularly to percutaneously deployed medical devices suitable for determining locations of cardiac features and/or ablating regions of cardiac tissue.


Description of the Related Art

Cardiac surgery was initially undertaken only by performing a sternotomy, a type of incision in the center of the chest, that separates the sternum (chestbone) to allow access to the heart. In the previous several decades, more and more cardiac operations are performed using percutaneous techniques, that is medical procedures where access to inner organs or other tissue is gained via a catheter.


Percutaneous surgeries benefit patients by reducing surgery risk, complications and recovery time. However, the use of percutaneous technologies also raises some particular challenges. Medical devices used in percutaneous surgery need to be deployed via narrow tubes called catheter sheaths, which significantly increase the complexity of the device structure. As well, doctors do not have direct visual contact with the medical tools used once they are placed within the body, and positioning the tools correctly and operating the tools successfully can often be very challenging.


One example of where percutaneous medical techniques are starting to be used is in the treatment of a heart disorder called atrial fibrillation. Atrial fibrillation is a disorder in which spurious electrical signals cause an irregular heart beat. Atrial fibrillation has been treated successfully in open heart methods using a technique know as the “Maze procedure”. During this procedure, doctors create lesions in a specific pattern in the left and right atriums that eliminate the spurious electrical signals. Such lesions were originally created using incisions, but are now typically created by ablating the tissue with RF energy. The procedure is performed with a high success rate under direct vision, but is relatively complex to perform percutaneously because of the difficulty in creating the lesions in the correct spots. Substantial problems, potentially leading to severe adverse results, may occur if the lesions are placed incorrectly.


Key factors which are needed to dramatically improve the percutaneous treatment of atrial fibrillation are enhanced methods for deployment, positioning, and operation of the treatment device. It is particularly important to know the position of the elements which will be creating the lesions relative to cardiac features such as the pulmonary veins and mitral valve.


Several methods have been previously developed for positioning percutaneously deployed medical devices with the heart. However, there are significant challenges associated with each of these methods. One method is to map the inside of the atrium by sensing electrical activity on the atrium wall. Devices that use such a method require intimate electrical contact with the atrium wall which is not always possible because of scar tissue and deposits. Also, such devices fail to accurately map the edges of the openings where the veins enter the atrium, which is important for correct placement of the ablation pattern. Other methods, such as using an array of ultrasonic transducers, are not practical as devices that make use of such methods will not fit through a catheter of a reasonable size (6-8 mm diameter). Yet another method for positioning the treatment device is to make use of an external system for providing navigation, such as a magnetic positioning system. These systems are very expensive and have difficulty delivering the resolution and accuracy needed for correct placement of ablation.


Atrial fibrillation is but one example of a cardiac surgery that requires improved navigation and deployment for percutaneous treatment. There are many others that require similar improvement, such as mitral valve repair.


Thus, there is a need for methods and apparatus that improve navigation and percutaneous deployment of medical devices, as well as determination of the relative position of cardiac features such as pulmonary veins and the mitral valve with respect to a medical device. There is a further need for methods and apparatus that allow the formation of lesions in a specified position relative to cardiac features such as pulmonary veins and the mitral valve.


BRIEF SUMMARY OF THE INVENTION

The present design of a medical device with enhanced capabilities for deployment, positioning and ablating within the heart employs a method for distinguishing tissue from blood and may be used to deliver superior positional information of the device relative to ports in the atrium, such as the pulmonary veins and mitral valve. The device may employ methods such as blood flow detection, impedance change detection or deflection force detection to discriminate between blood and tissue. The device may also improve ablation positioning and performance by using the same elements for discriminating between blood and tissue as are used for ablation. Other advantages will become apparent from the teaching herein to those of skill in the art.


At least one embodiment may be summarized as a method of operating a medical system including sensing at least one characteristic by each of a number of transducer elements carried by a device located in at least a portion of a bodily organ, the at least one characteristic indicative of at least one of a presence of a fluid (e.g., blood) and a presence of non-fluid tissue (e.g., wall of heart); computationally discriminating between the fluid and the non-fluid tissue based at least in part on the at least one characteristic sensed by at least some of the transducer elements; and providing information indicative of at least a position of the device in the bodily organ based on the computational discrimination between the fluid and the non-fluid tissue.


The method may further include ablating a portion of the non-fluid tissue in a bodily organ, for example the heart. The method may further include sensing an electrical potential of the non-blood tissue in the heart at least once after the ablating; and producing an indication based on the sensed electrical potential of the non-blood tissue indicative of whether the ablating was successful. Sensing at least one characteristic by each of a number of transducer elements may include sensing a permittivity of the fluid or the non-fluid tissue at each of a plurality of frequencies. Sensing at least one characteristic by each of a number of transducer elements may include sensing a force exerted on the sensor by the fluid or non-fluid tissue. Providing information indicative of at least a position of the device in the bodily organ based on the computational discrimination between the fluid and the non-fluid tissue may include providing information indicative of a three-dimensional pose of the device with respect to at least the portion of a heart. The method may further include intravascularly guiding the device to a desired position while at least a portion of the device is in an unexpanded configuration; selectively moving at least the portion of the device into an expanded configuration to position the transducer elements at least proximate the non-fluid tissue; selectively moving at least the portion of the device into the unexpanded configuration; and intravascularly retrieving the device from the desired position while at least a portion of the device is in the unexpanded configuration.


At least one embodiment may be summarized as a medical system including a device positionable in at least a portion of a bodily organ (e.g., a heart), the device including a plurality of transducer elements, at least some of the transducer elements responsive to at least one characteristic indicative of a presence of either a fluid (e.g., blood) or non-fluid tissue (e.g., wall of heart) a computing system having at least one processor and at least one memory that stores instructions, the computing system configured to computationally discriminate between the fluid and the non-fluid tissue based at least in part on the at least one characteristic sensed by at least some of the transducer elements; and at least one transducer configured to provide information indicative of at least a position of the device in the bodily organ based on the computational discrimination between the fluid and the non-fluid tissue.


The system may further include an ablation source, wherein at least some of the transducer elements may be coupled to an ablation source and selectively operable to ablate a portion of the non-fluid tissue in the heart. At least some of the transducer elements that are responsive to at least one characteristic indicative of a presence of either the fluid or the non-fluid tissue in the bodily organ may also be responsive to electrical potential of the non-fluid tissue. At least some of the transducer elements may be responsive to electrical potentials of the non-fluid tissue, and the computing system may be further configured to produce an indication indicative of whether the ablation was successful based on at least one sensed electrical potential of the non-fluid tissue. At least a portion of the device may be selectively moveable between an unexpanded configuration and an expanded configuration, the device sized to be delivered intravascularly when at least the portion of the device is in the unexpanded configuration, and the transducer elements positioned sufficient proximate the non-fluid tissue to sense the at least one characteristic in the expanded configuration. The system may further include a catheter having a proximal end and a distal end opposed to the proximal end, the device coupled to the catheter at the distal end thereof; at least one communications path communicatively coupling the transducer elements and the computing system, the communications path including a multiplexer and a demultiplexer, the multiplexer on a computing system side of the communications path and the demultiplexer on a device side of the communications path.


At least one embodiment may be summarized as a method of operating a device in at least a portion of a heart, including sensing at least one characteristic by each of a number of transducer elements carried by the device located in at least the portion of the heart, the at least one characteristic indicative of at least one of a presence of blood and a presence of non-blood tissue; computationally discriminating between the blood and the non-blood tissue based at least in part on the at least one characteristic sensed by at least some of the transducer elements; providing information indicative of a position of the device in the heart based on the discrimination between the blood and the non-blood tissue; sensing an electrical potential of the non-blood tissue in the heart; and providing an indication based on the sensed electrical potential of the non-blood tissue.


The method may further include ablating a portion of the tissue in the heart, wherein sensing an electrical potential of the non-blood tissue in the heart may occur at least once after the ablating. The method may further include evaluating the sensed electrical potential of the non-blood tissue in the heart to determine whether the ablating was successful.


At least one embodiment may be summarized as a medical system including a device positionable in at least a portion of a heart, the device including a plurality of transducer elements at least some of the transducer elements responsive to at least one characteristic indicative of at least one of a presence of blood and a presence of non-blood tissue and at least some of the transducer elements responsive to an electrical potential of the non-blood tissue in the heart; a computing system having at least one processor and at least one memory that stores instructions, the computing system configured to computationally discriminate between the blood and the non-blood tissue based at least in part on the at least one characteristic sensed by at least some of the transducer elements; and at least one transducer configured to provide information indicative of a position of the device in the heart based on the computational discrimination between the blood and the non-blood tissue and provide an indication based on the sensed electrical potential of the non-blood tissue.


The system may further include an ablation source, wherein at least some of the transducer elements may be coupled to an ablation source and selectively operable to ablate a portion of the non-blood tissue in the heart. The system may further include a switch operable to selectively couple the transducer elements between an ablation mode and a sense mode, where the transducer elements may ablate the non-blood tissue in the ablation mode and may sense the at least one characteristic in the sense mode. At least some of the transducer elements that are responsive to at least one characteristic indicative of a presence of either blood or non-blood tissue may also be responsive to electrical potential of the non-blood tissue. At least a portion of the device may be selectively moveable between an unexpanded configuration and an expanded configuration, the device sized to be delivered intravascularly when at least the portion of the device is in the unexpanded configuration, and the device sized to position the transducer elements sufficiently proximate the non-blood tissue to sense the at least one characteristic in the expanded configuration. The transducer elements may include at least one of a conductive trace on a flexible electrically insulative substrate, a conductive wire, a conductive tube, a carbon fiber material and a polymeric piezoelectric material. The device may include a number of flexible electrically insulative substrates that deform between an unexpanded configuration and an expanded configuration.


At least one embodiment may be summarized as a device to be inserted intravascularly, including a shaft moveable with respect to a catheter member; at least a first helical member configured to move between a radially unexpanded configuration and a radially expanded configuration in response to the movement of the shaft with respect to the catheter, the device sized to be delivered intravascularly when at least the first helical member is in the unexpanded configuration; and a plurality of transducer elements that move in response to the movement of the first helical member between the radially unexpanded configuration and the radially expanded configuration, at least some of the transducer elements responsive to a characteristic of at least one of a fluid and a non-fluid tissue.


The device may further include at least a second helical member configured to move between a radially unexpanded configuration and a radially expanded configuration in response to the movement of the shaft with respect to the catheter. The first helical member may carry some of the transducer elements and the second helical member may carry some of the transducer elements. The first helical member may be disposed radially spaced about the shaft. The first helical member may be wound in one of a clockwise or a counterclockwise orientation with respect to the shaft and the second helical member may be wound in the other of the clockwise or the counterclockwise orientation with respect to the shaft. The device may further include a number of elongated ribs physically coupled between a proximate and a distal end of the first helical member. The elongated ribs may each form a respective flexible electrically insulative substrate and at least some of the transducer elements may comprise respective electrically conductive traces carried by the flexible electrically insulative substrate. The shaft may be axially moveable with respect to the catheter member between an extended position and a withdrawn position, a distal end of the shaft spaced relatively closer to an end of the catheter member in the withdrawn position than in the extended position, where the first helical member is in the unexpanded configuration when the shaft is in the extended position and is in the expanded configuration when the shaft is in the withdrawn position. The shaft may be rotatably moveable with respect to the catheter member between an extended position and a withdrawn position, a distal end of the shaft spaced relatively closer to an end of the catheter member in the withdrawn position than in the extended position, where the first helical member is in the unexpanded configuration when the shaft is in the extended position and is in the expanded configuration when the shaft is in the withdrawn position. The shaft may extend at least partially through a lumen of the catheter member to allow manipulation of the device from a position externally located from a patient. At least some of the transducer elements may be responsive to convective cooling from a flow of blood over the transducer elements. At least some of the transducer elements may be responsive to a permittivity at each of a plurality of frequencies. At least some of the transducer elements may be responsive to a force. At least some of the transducer elements may comprise a polymeric piezoelectric material. At least some of the transducer elements may be responsive to an electrical potential of a portion of the non-blood tissue. At least some of the transducer elements may include an electrically conductive trace carried by a flexible electrically insulative substrate. The first helical member may form a flexible electrically insulative substrate and at least some of the transducer elements may comprise respective electrically conductive traces carried by the flexible electrically insulative substrate. At least some of the transducer elements may include an electrically conductive wire. At least some of the transducer elements may include an electrically conductive tube. At least some of the transducer elements may include an electrically conductive carbon fiber.


At least one embodiment may be summarized as a method of operating a device including at least a first helical member and a plurality of transducer elements that are responsive to at least one characteristic of non-blood tissue, comprising: guiding a device in an unexpanded configuration intravascularly to a desired position; and expanding at least the first helical member of the device into an expanded configuration such that the plurality of transducer elements are positioned to sense the at least one characteristic over a substantial portion of the non-blood tissue.


The expanding at least the first helical member may include axially moving a shaft that extends at least partially through a lumen of a catheter member in a first direction. The expanding at least first helical member may include rotatably moving a shaft that extends at least partially through a lumen of a catheter member in a first direction. The method may further include retracting at least the first helical member into the unexpanded configuration; and intravascularly guiding the device in the unexpanded configuration to remove the device. The retracting at least the first helical member into the unexpanded configuration may include at least one of axially or radially moving the shaft that extends at least partially through the lumen of the catheter member in an opposite direction than moved when expanded.


At least one embodiment may be summarized as a medical device, including at least a first inflatable member having at least one chamber and at least one port that provides fluid communication with the chamber, the first inflatable member configured to move between an unexpanded configuration and an expanded configuration in response to a change of a pressure in the chamber, the device sized to be delivered intravascularly when at least the first inflatable member is in the unexpanded configuration; a plurality of transducer elements that move in response to the movement of the first inflatable member between the radially unexpanded configuration and the radially expanded configuration, at least some of the transducer elements responsive to a characteristic of at least one of a fluid and a non-fluid tissue.


The first inflatable member may have at least one passage that provides fluid communication across the first inflatable member. The at least one passage may provide fluid communication between an upstream position and a downstream position with respect to a position of the inflatable member when positioned in a cardiovascular structure. The at least one passage may be formed by a reinforced portion of the first inflatable member. The reinforced portion of the first inflatable member may include at least a rib, an elastic member, and a thickened portion of a wall that forms the passage. The port may be coupled to a lumen of a catheter member to allow fluid communication with the chamber from a fluid reservoir that is externally located with respect to a patient. At least some of the transducer elements may be responsive to convective cooling from a flow of blood over the transducer elements. At least some of the transducer elements may be responsive to a permittivity at each of a plurality of frequencies. At least some of the transducer elements may be responsive to a force. At least some of the transducer elements may comprise a polymeric piezoelectric material. At least some of the transducer elements may be responsive to an electrical potential of a portion of the non-blood tissue. At least some of the transducer elements may include an electrically conductive trace carried by a flexible electrically insulative substrate. The first helical member may form a flexible electrically insulative substrate and at least some of the transducer elements may comprise respective electrically conductive traces carried by the flexible electrically insulative substrate. At least some of the transducer elements may include an electrically conductive wire. At least some of the transducer elements may include an electrically conductive tube. At least some of the transducer elements may include an electrically conductive carbon fiber.


At least one embodiment may be summarized as a method of operating a device including at least a first inflatable member and a plurality of transducer elements that are responsive to at least one characteristic of non-blood tissue, comprising: guiding a device in an unexpanded configuration intravascularly to a desired position; and inflating at least the first inflatable member of the device into an expanded configuration such that the plurality of transducer elements are positioned to sense the at least one characteristic over a substantial portion of the non-blood tissue.


Inflating at least the first helical member may include providing a fluid to a chamber of the first inflatable member through a lumen of a catheter member. The method may further include deflating at least the first inflatable member into the unexpanded configuration; and intravascularly guiding the device in the unexpanded configuration to remove the device. Deflating at least the first helical member into the unexpanded configuration may include removing the fluid from the chamber through the lumen of the catheter member.





BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, identical reference numbers identify similar elements or acts. The sizes and relative positions of elements in the drawings are not necessarily drawn to scale. For example, the shapes of various elements and angles are not drawn to scale, and some of these elements are arbitrarily enlarged and positioned to improve drawing legibility. Further, the particular shapes of the elements as drawn, are not intended to convey any information regarding the actual shape of the particular elements, and have been solely selected for ease of recognition in the drawings.



FIG. 1 is a cutaway diagram of a heart showing a medical device according to one illustrated embodiment percutaneously placed in a left atrium of the heart.



FIG. 2 is a schematic diagram of a treatment system according to one illustrated embodiment, including, a control unit, a display, and a medical device having an expandable frame and a leaf shaped assembly of elements.



FIG. 3 is a broken isometric diagram of a portion of an atrium and a number of elements showing how the elements can sense convective cooling to locate a position of ports.



FIG. 4A is a top plan view of element construction for flow sensing.



FIG. 4B is a top plan view according to yet another illustrated embodiment



FIG. 4C is a top plan view according to yet another illustrated embodiment.



FIG. 4D is a top plan view according to yet another illustrated embodiment.



FIG. 4E is a top plan view according to yet another illustrated embodiment.



FIG. 4F is a top plan view according to yet another illustrated embodiment.



FIG. 4G is a top plan view according to yet another illustrated embodiment.



FIG. 4H is a top plan view according to yet another illustrated embodiment.



FIG. 5 is a diagram showing how common leads can be shared by elements used for flow sensing.



FIG. 6A is a schematic diagram showing an example of techniques used to improve precision in measuring voltage drops across elements.



FIG. 6B is a schematic diagram showing an example of techniques used to improve precision in measuring voltage drops across elements.



FIG. 6C is a schematic diagram showing an example of techniques used to improve precision in measuring voltage drops across elements.



FIG. 7 is a circuit diagram of an example of a system used for flow sensing, port location, and tissue ablation.



FIG. 8 is a circuit diagram of a second example of a system used for flow sensing, port location, and tissue ablation.



FIG. 9 is a circuit diagram of a third example of a system used for flow sensing, port location, and tissue ablation.



FIG. 10A is a top plan view of a structure having distinct permittivity sensor elements, temperature sensor elements and ablation elements, according to one illustrated embodiment.



FIG. 10B is a top plan view of a structure having integrated permittivity sensor and ablation elements, according to one illustrated embodiment.



FIG. 10C is a top plan view of a structure having integrated permittivity sensor and ablation elements, according to another illustrated embodiment.



FIG. 10D is a top plan view of a structure having integrated permittivity and temperature sensor and ablation elements, according to one illustrated embodiment.



FIG. 11 is a circuit diagram of an example of a system used for permittivity sensing, port location, and tissue ablation.



FIG. 12A is a top plan view of a structure having distinct force sensor elements, temperature sensor elements and ablation elements, according to one illustrated embodiment.



FIG. 12B is top plan view of a structure having force sensor elements that are distinct from integrated temperature sensor and ablation elements, according to one illustrated embodiment.



FIG. 12C is a top plan view of a leaf shaped structure having force sensor elements that are distinct from integrated temperature sensor and ablation elements, according to one illustrated embodiment.



FIG. 13 is a circuit diagram of an example of a system used for force sensing, port location, and tissue ablation.



FIG. 14A is an example of a frame using multiple helix shaped members.



FIG. 14B is an example of a frame using multiple helix shaped members.



FIG. 15A is an example of a frame using a single helix shaped member and multiple ribs.



FIG. 15B is an example of a frame using a single helix shaped member and multiple ribs



FIG. 15C is an example of a frame using a single helix shaped member and multiple ribs.



FIG. 16A is an example of an inflatable frame with ports for blood flow.



FIG. 16B is an example of an inflatable frame with ports for blood flow.



FIG. 17A is a top plan view of a joint assembly structure, according to one illustrated embodiment.



FIG. 17B is a top plan view of a joint assembly structure, according to another illustrated embodiment.



FIG. 17C is a top plan view of a joint assembly structure, according to another illustrated embodiment.



FIG. 17D is a top plan view of a joint assembly structure, according to another illustrated embodiment.



FIG. 17E is a top plan view of a joint assembly structure, according to another illustrated embodiment.



FIG. 18A is a top plan view of a joint assembly structure, according to another illustrated embodiment.



FIG. 18B is a top plan view of a joint assembly structure, according to another illustrated embodiment.





DETAILED DESCRIPTION OF THE INVENTION

In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments of the invention. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures associated with RF ablation and electronic controls such as multiplexers have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments of the invention.


Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is as “including, but not limited to.”


The word “ablation” should be understood to mean any disruption to certain properties of the tissue. Most commonly the disruption is to the electrical conductivity and is achieved by heating, which could be either resistive or by use of Radio Frequencies (RF). Other properties, such as mechanical, and other means of disruption, such as optical, are included when the term “ablation” is used.


Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.


As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.


The headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.


Overview of Device and Mapping Methods


Various embodiments of percutaneously or intravascularly deployed medical devices are described herein. The medical devices are capable of expanding into a cavity within a body and sensing characteristics (e.g., convective cooling, permittivity, force) that distinguish between blood and non-blood tissue. Such sensed characteristic allow a medical system to map the cavity, for example using positions of openings or ports into and out of the cavity to determine a position and/or orientation (i.e., pose) of the medical device in the cavity. The medical devices may also be capable of ablating tissue in a desired pattern within the cavity. The medical devices may further be capable of sensing characteristics (e.g., electrical activity), indicative of whether ablation has been successful.


An example of the mapping performed by the medical treatment devices would be to locate the position of the four openings leading to the pulmonary veins as well as the mitral valve on the interior surface of the left atrium. The mapping is based on locating such openings by differentiating between blood and non-blood tissue. There are many ways to differentiate non-blood tissue from a liquid such as blood or to differentiate non-blood tissue from an opening in case a liquid is not present. By the way of example, three approaches will be detailed in the disclosure:


1. One approach to determining the locations is to use the convective cooling of heated transducer elements by the blood. A slightly heated mesh of transducer elements positioned adjacent to the non-blood tissue that forms walls of the atrium and across the openings or ports of the atrium will be cooler at the areas which are spanning the openings or ports carrying blood flow.


2. Another approach to determining the locations is to make use of the differing change in dielectric constant as a function of frequency between blood and non-blood tissue. A set of transducer elements positioned around the non-blood tissue that forms the interior surface of the atrium and across the openings or ports of the atrium monitor the ratio of the dielectric constant from 1 KHz to 100 KHz. Such can be used to determine which of those transducer elements are not proximate to non-blood tissue, which is indicative of the locations of openings or ports.


3. Yet another approach to determining the locations is to sense a position of the non-blood tissue that forms the atrium walls using transducer elements that sense force (i.e., force sensors). A set of force detection transducer elements positioned around the non-blood tissue that forms the interior surface of the atrium and across the openings or ports of the atrium can be used to determine which of the transducer elements are not in contact with the non-blood tissue, which is indicative of the locations of openings or ports.



FIG. 1 shows a medical device 100 useful in diagnosing and/or treating a bodily organ, for example a heart 102, according to one illustrated embodiment.


The medical device 100 may be percutaneously and/or intravascularly inserted into a portion of the heart 102, for example in a left atrium 104 of the heart 102. In this example, the medical device is delivered via a catheter 106 inserted via the superior vena cava 108 and penetrating the transatrial septum 110 from a right atrium 112.


The catheter 106 may include one or more lumens 114. The lumen(s) 114 may carry one or more communications and/or power paths, for example one or more wires 116. The wires 116 provide connections to the medical device 100 that are accessible externally from a patient in which the medical device 100 is inserted.


As discussed in more detail herein, the medical device 100 comprises a frame 118 which expands (shown in expanded configuration in FIG. 1) upon delivery to the left atrium 104 to position a plurality of transducer elements 120 (only three called out in FIG. 1) proximate the interior surface or non-blood tissue 122 of the left atrium 104. At least some of the transducer elements 120 of the medical device are used to sense a physical characteristic of blood and/or tissue that may be used to determine a position and/or orientation or pose of the medical device 100 in the left atrium 104. For example, the transducer elements 120 may be used to determine a location of pulmonary vein ostiums 124 and/or a mitral valve 126. At least some of the transducer elements 120 of the medical device 100 may be used to selectively ablate non-blood tissue, for example portions of the interior surface 122 of the left atrium 104. For example, some of the elements may be used to ablate a pattern around the openings, ports or pulmonary vein ostiums 124, for instance to reduce or eliminate the occurrence of atrial fibrillation.



FIG. 2 shows a medical device 200 according to one illustrated embodiment.


The medical device 200 takes the form of an expandable electrode grid or array 202, including a plurality of flexible strips 204 (three called out in FIG. 2). A plurality of transducer elements 206 (four called out in FIG. 2) form a two- or three-dimensional grid or array capable of mapping the inside surface of a cavity or lumen without requiring mechanical scanning. An expandable frame 208 may be used to force flexible strips 204 against the inside walls of the cavity. The expandable frame 208 may include one or more resilient members. For example, the expandable frame 208 may consist of or include a shape memory material, for instance Nitinol. Such may be useful for both accurate location of the parts, position and/or orientation (i.e., pose) and/or for successful ablation of a desired pattern.


The expandable frame 208, as well as flexible strips 204 can be delivered and retrieved via a catheter member, for example a catheter sheath introducer 210, which in some embodiments may have a diameter of about 8 mm or smaller. Flexible strips 204 may be made of one or more thin layers of Kapton (polyimide), for instance 0.1 mm thick. Transducer elements (e.g., electrodes and/or sensors) 206 may be built on the flexible strips 204 using standard printed circuit board processes. An overlay of a thin electrical insulation layer (e.g., Kapton about 10-20 microns thick) may be used to provide electrical insulation, except in areas needing electrical contact to blood and non-blood tissue. In some embodiments, the flexible strips 204 can form an elongated cable 216 of control leads 218, for example by stacking multiple layers, and terminating in a connector 220. The electrode grid or array 202 is typically disposable.


The medical device 200 may communicate with, receive power from and/or be controlled by a control system 222. The control system 222 may include a computing system 224 having one or more processors 226 and one or more memories 228 that store instructions that are executable by the processors 226 to process information received from the medical device 200 and/or to control operation of the medical device 200, for example activating selected transducer elements 206 to ablate non-blood tissue. The control system 222 may include an ablation source 230. The ablation source 230 may, for example, provide electrical power, light or low temperature fluid to the selected transducer elements to cause ablation. The control system 222 may also include one or more user interface or input/output (I/O) devices, for example one or more displays 232, speakers 234, keyboards, mice, joysticks, track pads, touch screens or other transducers to transfer information to and from a user, for example a care provider such as a medical doctor or technician. For example output from the mapping process may be displayed on a display 232.


While the disclosed systems are described with examples of cardiac mapping, the same or similar systems may be used for mapping other bodily organs, for example gastric mapping, bladder mapping, arterial mapping and mapping of any lumen or cavity into which the medical device 204 may be introduced.


The term “transducer element” in this disclosure should be interpreted broadly as any component capable of distinguishing between blood and tissue, sensing temperature, creating heat, ablating tissue and measuring electrical activity of a non-blood tissue surface, or any combination thereof. A transducer element may be constructed from several parts, which may be discrete components or may be integrally formed.


Sensing Convective Cooling



FIG. 3 shows a portion of a medical device 300, according to one illustrated embodiment.


The portion of the medical device 300 is particularly suitable to sense convective cooling. The medical device 300 includes miniature transducer elements 302a, 302b, 302c (collectively 302) capable of producing heat. The transducer elements 302 may, for example, be made of insulated resistive wire, such as Nickel, or Nickel-iron composition. The resistive wire may be mounted on an expandable frame 304. In this embodiment, the expandable frame 304 may also be made of a material that has high impedance. Current passed through each transducer element 302 raises the temperature of the transducer element 302 by a nominal amount. A rise of 0.5-3.0 degrees Celsius above normal blood temperature has been found to be sufficient in most cases. The power required to raise the temperature in this particular embodiment is about 10-50 mW per transducer element 302. A central one of the transducer elements 302b, which is placed across the opening, port of ostium 306 of the pulmonary vein 308 will be cooled by blood flow more than the neighboring transducer elements 302a, 302c which are adjacent to the inner or interior surface or non-blood tissue 310 that forms the wall of the heart. Transducer elements 302 which are found to be cooler on expandable frame 304 indicate the locations of openings or ports 306 in the non-blood tissue 310 that forms the wall of the heart. This embodiment does not require intimate contact with the bodily tissue 310 of the heart wall, as even a few millimetres from the openings or ports 306 the cooling effect is significant compared to the cooling effect a few millimetres from the non-blood tissue 310 of the heart wall. The back side of the transducer elements 302 may be thermally insulated for improved performance of both sensing and ablation. Using a flat ribbon for the expandable frame 304 may be advantageous. A cross section of a ribbon expandable frame 304 may, for example have dimensions of 0.2×2 mm for stainless steel or 0.3×2.5 mm for Nitinol. The insulation on the back side of the transducer elements 302 may take the form of a coat of silicone rubber.


If the transducer elements 302 are made of a material that has a significant change in resistance with temperature, the temperature drop can be determined from the resistance of the transducer element 302. The resistance can be determined by measuring the voltage across the transducer element 302 for a given current, or alternatively by measuring the current across the transducer element 302 for a given voltage, for example via a Wheatstone bridge circuit. Thus, some embodiments may take advantage of convective cooling by the flow of blood, at least some of the transducer elements 302 functioning as a hot wire anemometer. Nickel wire is a suitable material to use, as nickel is inert, highly resistive and has a significant temperature coefficient of resistance (about 0.6% per deg C.). Since the resistance of the transducer elements 302 is low (typically less than 5 ohm), the electrical noise is very low and temperature changes as low as 0.1-1 deg can be detected. There are several techniques to improve on this sensitivity. One method is to sample the voltage waveform in synchronization with the heart rate. Another is to remove the average voltage via AC coupling and only amplify the voltage change or derivative. Yet another method to reduce the electrical noise is to pass the signal through a digital band pass filter having a center frequency tracking the heart rate.



FIGS. 4A-4G show examples of alternative ways of constructing transducer elements. Each of the embodiments of FIGS. 4A-4F show transducer elements which have been constructed using printed circuit board (PCB) substrates. These transducer elements may be affixed to a structure similar to the expandable frame 208 shown in FIG. 2, which may be made from a material such as Nitinol. Alternatively, the PCB substrates may be of such a thickness that the PCB substrates can form the expandable frame. The PCB substrates should be flexible enough to conform to the non-blood tissue, but stiff enough such that the PCB substrate does not buckle. PCB substrates may, for example, be made from Kapton®. A PCB substrate made of Kapton® having a thickness, for instance, of approximately 0.1 to 0.3 mm may be suitable. The transducer elements could also be constructed using discrete components. FIGS. 4G-4H show embodiments that do not employ PCB substrates.



FIG. 4A shows a PCB substrate 400a that carries a combination of transducer elements, in particular sensor transducer elements 402a, 402b (collectively 402, only two called out in FIG. 4A) which sense convective cooling and ablation transducer elements 404a, 404b (collectively 404, only two called out in FIG. 4A) which are operable to ablate non-blood tissue. Leads, collectively 406, extend to respective ones of the transducer elements 402, 404. The leads 406 may be coupled to a control system (e.g., control system 222 of FIG. 2), which may provide communications, power and/or control with the transducer elements 402, 404.



FIG. 4B shows a PCB substrate 400b that carries a number of combined sensor and ablation transducer elements 408a, 408b (collectively 408, only two called out in FIG. 4B) that both sense flow and ablate non-blood tissue. Such a feature may be a significant advantage since a medical device with combined sensor and ablation transducer elements 408 can measure flow at the exact spot that ablation will occur, while requiring fewer parts, thus improving precision and reducing size. In this embodiment, each combined sensor and ablation transducer element 408 has respective leads, collectively 410, coupled to a control system (e.g., control system 222 of FIG. 2).


A combined sensor and ablation transducer element 408 that can be used for both sensing flow and ablating can be made using standard PCB construction processes. For example, a 2-4 mil copper trace on a Kapton® substrate can be used. Copper changes resistance sufficiently with temperature to be used to determine blood flow in the manner discussed above. Copper can also be used as an ablation element by applying sufficient current through the copper to cause the combined sensor and ablation transducer element 408 to heat resistively, for example to a temperature above 60° C. Power in the range of approximately 130-250 mW delivered to a copper pattern that has external dimensions of 3 mm×10 mm and is thermally insulated on the side away from the non-blood tissue may be sufficient to transmurally ablate a 3 mm deep section of the non-blood tissue that forms the atrium wall. In this approach, the non-blood tissue is heated by conduction from the copper combined sensor and ablation transducer element 408. When heating the non-blood tissue by conduction, the combined sensor and ablation transducer element 408 may be electrically insulated from the non-blood tissue.


Alternatively, the combined sensor and ablation transducer element 408 can also be used to ablate non-blood tissue by using the combined sensor and ablation transducer element 408 as an electrode for delivering RF energy to the non-blood tissue. In this scenario, electrical current is transferred directly to the non-blood tissue and the non-blood tissue is resistively heated by the current flow. When delivering RF energy, a preferred method may be to have low electrical impedance between the combined sensor and ablation transducer element 408 and the non-blood tissue. Delivering RF energy is also possible if the combined sensor and ablation transducer element 408 is capacitively coupled to the non-blood tissue, so long as the impedance at the frequency of RF energy being used is sufficiently low—typically under a few kilo ohms or less for a combined sensor and ablation transducer element of the size mentioned above. Note that in the case where the combined sensor and ablation transducer element 408 has a low electrical impedance connection to the non-blood tissue for low frequencies, it is also possible to use the combined sensor and ablation transducer element 408 to sense an electrical potential in the non-blood tissue that forms the heart wall, for example to generate an electro-cardiogram. Thus it is possible for the same combined sensor and ablation transducer element 408 to sense flow, sense electrical potential of the non-blood tissue that forms the heart wall, and ablate non-blood tissue.



FIG. 4C shows a PCB substrate 400c that carries a number of combined flow sensor, ablation and temperature transducer elements 412a, 412b (collectively 412, only two called out in FIG. 4C) that can be used to sense flow, ablate non-blood tissue and sense or monitor temperature, for example for ablation control. A single control lead, collectively 414, is required per combined flow sensor, ablation and temperature transducer element 412, plus a common return lead 416 to the multiple combined flow sensor, ablation and temperature transducer elements 412. The combined flow sensor, ablation and temperature transducer element 412 can take the form of a low resistance resistor, for example a resistor formed by a 30-100 micron wide trace of 10-30 micron copper foil. Such a resistor has a typical resistance of 2-20 ohms and can be used as a combined flow sensor, ablation and temperature transducer element 412 to sense flow, perform ablation and sense temperature. When used as a temperature sensor, the resistance changes about 1% for a 2 degree C. temperature change.



FIG. 4D shows a PCB substrate 400d that carries a number of adjacent transducer elements 420a, 420b (collectively 420, only two called out in FIG. 4D). The transducer elements 420 share common control leads 422. This feature is an advantage as it dramatically reduces the number of leads 422 needed to return to the control system (e.g., control system 222 of FIG. 2).



FIG. 5 shows an expanded example of a portion of the embodiment of FIG. 4D positioned proximate non-blood tissue 500. To determine flow by measuring the resistance of transducer element 420b, the voltage at a lead 422a and lead 422b should be made equal and the voltage at a lead 422c and lead 422d should be made equal, but to a different voltage than that of lead 422a and lead 422b. In this condition, negligible current will flow through transducer element 420a and transducer element 420c. Therefore, the current flowing through lead 422b and lead 422c is the same as the current flowing through the transducer element 420b, and the resistance of the transducer element 420b can be calculated in a straightforward manner using the equation

V=I/R.


To cause the transducer element 420b to heat to a temperature sufficient to cause ablation, while not causing ablation at transducer element 420a and transducer element 420c:

    • the voltage at lead 422c and lead 422d should be made equal;
    • the voltage at lead 422b should be made higher than the voltage at lead 422c such that sufficient power is delivered to the transducer element 420b to cause the transducer element 420b to heat to the appropriate temperature; and
    • the voltage at lead 422a should be set a value that is a fraction of that at lead 422b such that the power delivered to the transducer element 420a is not sufficient to cause the temperature of the transducer element 420a to rise enough for tissue ablation.


For example, if the voltages at lead 422c and lead 422d are set to 0 v, voltage at lead 422b is set to n volts and voltage at lead 422a is set to ⅔ n volts, the power delivered to the transducer element 420a will be only 11% of that delivered to the transducer element 420b. This technique of having adjacent transducer elements 420 share common leads 422 can, for example, be used in a elongated one-dimensional line of connected transducer elements 420 or may be applied to transducer elements 420 connected in two-dimensional (as illustrated in FIGS. 8, 17A-17C, 18A and 18B) or three-dimensional arrays.



FIG. 4E shows a PCB substrate 400e that carries a number of transducer elements 424a, 424b (collectively 424, only two called out in FIG. 4E). The transducer elements 424 are coupled to leads 426, similar to leads 422 of the embodiment of FIG. 4D, and to additional leads 428, which have been added to measure the voltage at the ends of the transducer elements 424. This feature advantageously increases the accuracy in determining the resistance, and thus temperature, of the transducer elements 424. The leads 426 that provide the current to the transducer elements 424 typically have a small voltage drop across them that can affect the accuracy of the resistance calculation of the transducer element 424. These additional leads 428 will have a very limited amount of current flowing through them, and thus the voltage drop through the leads 428, even for a distance of several meters will be negligible, and the voltage drop across the transducer elements 424 can be determined accurately.



FIG. 4F shows a flexible PCB substrate 400f that forms a leaf shaped assembly. An expandable frame (e.g., expandable frame 208 of FIG. 2) may be covered by several of these leaf shaped assemblies, each of which will cover or be proximate a respective portion of the non-blood tissue that forms the wall of the body organ when in use. Each of the leaf shaped assemblies caries a plurality of transducer elements 430a, 430b (collectively 430, only two called out in FIG. 4F). In this example, the transducer elements 430 are coupled together as described above embodiment of FIG. 4D. Leads 432 couple each transducer 430 to a control system (e.g., control system 222 of FIG. 2). The leads 432 may couple power, communications and/or control signals. The leads 432 may, for example, provide for electrically conductive coupling, inductive coupling, capacitive coupling, optical coupling, galvanic coupling, fluidic coupling and/or thermal coupling.


There are other approaches for creating the transducer elements that do not rely on a PCB. FIGS. 4G and 4H provide examples of some of these.



FIG. 4G shows transducer elements 440a, 440b (collectively 440, only two called out in FIG. 4G) that are made from a bundle of carbon fibers. Leads 442 couple the transducer elements 440 to a control system.



FIG. 4H shows transducer elements 450a, 450b (collectively 450, only two called out in FIG. 4H) that are made directly from a hollow tube of a metal such as stainless steel or alternatively from wire. Leads 452 couple the transducer elements 450 to a control system.


The structures of the embodiments of FIGS. 4G and 4H may be advantageous over other embodiments, since the structures are simple to assemble, and can be used directly as the supporting structure itself. Leads 442, 452 are connected at intervals to the carbon fibre or metal. The material between the leads 442, 452 form the transducer elements 440, 450. In order to function properly, these transducer elements 440, 450 should have the electrical properties the same as or similar to the electrical properties indicated previously. These two embodiments provide an example of where the same transducer element 440, 450 can sense flow, sense or measure temperature, deliver the ablation energy, and/or be an integral component of the supporting structure.



FIGS. 4A-4H show examples of many transducer element configurations that are possible. From the previous descriptions, it is important to note that a single transducer element can sense blood flow in order to distinguish between blood and non-blood tissue, sense an electrical potential of the non-blood tissue (e.g., heart wall), ablate non-blood tissue, sense or measure temperature, and/or form an integral component of the supporting structure, or any combination of these functions. The ablation may be performed by causing the transducer element to heat, or by delivering energy, such as RF directly to the non-blood tissue. Also, transducer elements can be constructed using individual leads, common ground lead, or shared leads. Each lead may have a separate lead that runs in parallel to it for the purpose of accurately determining voltage potential directly at the transducer element. As well, the examples discussed methods of sensing temperature that relied on changes in resistance. However, it is certainly possible to use other temperature sensing methods, such as thermistors or thermocouples in conjunction with the transducer elements that produce heat. For example, the sensing transducer element of the embodiment of FIG. 4A could be a thermistor, thermocouple or temperature sensitive diode.



FIG. 7 shows an embodiment of an electric circuit 700 that can be used to distinguish between blood and non-blood tissue by sensing flow of blood.


In this example, transducer elements 702a-702d (collectively 702) may be resistive elements, for example formed from copper traces on a flexible printed circuit board substrate, or resistive wires mounted on a structure. Each transducer element 702 is connected by electronic transducer selection switches 704a-704h (collectively 704) to a single pair of wires 706a, 706b (collectively 706) that provide a path out of the body via a cable 708. The transducer selection switches 704 may, for example be FET or MOSFET type transistors. The transducer selection switches 704 will typically need to carry significant power during the ablation phase. The cable 708 may extend through a lumen of a catheter or may otherwise form part of a catheter structure.


The transducer selection switches 704 are selected by signals applied by a demultiplexer (selector) 710. The demultiplexer 710 may be controlled by a small number of wires 712 (or even a single wire if data is relayed in serial form). The wires 706, 712 extend out of the body via the cable 708. The transducer selection switches 704 and the demultiplexer 710 may be built into a catheter (e.g., catheter 106 of FIG. 1) near a distal end or point of deployment. The transducer selection switches 704 and demultiplexer 710 may be located within or near the expandable frame (e.g., expandable frame 208 of FIG. 2) in order to minimize the number and/or length of connecting wires extending through the catheter.


At the other or proximate end of the catheter are a mode selection switch 726 and multiplexer 714. The mode selection switch 726 is operable to select between a flow sensing mode (position shown in the drawing) and an ablation mode (second position of the mode selection switch 726). In flow sensing mode, a current is created by a voltage source 716 and resistor 718 (forming an approximate current source) and routed into a transducer element 702 selected via transducer selection switches 704. The two transducer selection switches 704 that are connected to a given one of the transducer elements 702 to be used to sense flow, are set to be closed and the remainder of the transducer selection switches 704 are set to be open. The voltage drop across the transducer element 702 is measured via an Analog-to-Digital converter (ADC) 720 and fed to the control computer 722.


It may be advantageous to use alternating current or a combination of alternating current and direct current for sensing and ablation. For example, direct current for ablation and alternating current for sensing. Alternating current approaches may also prevent errors from electrochemical potentials which could be significant if different metals come in touch with blood.


Determination of the location of the openings or ports into the chamber may be achieved by turning on all of transducer elements 702 sequentially or in groups and determining a temperature by measuring the resistance of each transducer element 702. A map of the temperature of the transducer elements 702 may be formed in control computer 722 or the control computer 722 may otherwise determine a position and/or orientation or pose of the device in the cavity. The transducer elements 702 with lower temperatures correspond to the openings or ports leading to the veins or valves.


When mode selection switch 726 is set to select ablation, an ablation power source 724 is connected sequentially to the transducer elements 702 that are selected by the control computer 722 by addressing the multiplexer 714, which in turn controls the transducer selection switches 704 via the demultiplexer 710. The ablation power source 724 may be an RF generator, or it may be one of several other power sources, several of which are described below. If ablation power source 710 is an RF generator, the configuration of FIG. 7 implies unipolar RF ablation, in which current is fed into the non-blood tissue and passes to a ground connected to the body. The current that passes through the non-blood tissue causes the non-blood tissue to heat. However, bipolar ablation can be used as well. Other sources of ablation can be used besides radio frequency. Frequencies from DC to microwaves can be used, as well as delivery of laser power via optical fibers or cryogenics via thin tubes. For laser ablation, the transducer selection switches 704 may take the form of optical switches. For cryogenic ablation, the transducer selection switches 704 take the form of suitable valves and/or actuators (e.g., solenoids). Alternatively, the bottom terminal of the lower switch of mode selection switch 726 may be coupled directly to ground. In this configuration, the ablation power source 724 can be configured to supply current with frequencies from DC to microwave, which will cause the selected transducer elements 702 to heat directly and produce ablation via thermal conduction.


During ablation it may be desirable to monitor the temperature of the non-blood tissue. The ideal temperature range for the non-blood tissue during ablation is typically 50-100° C. Since the example includes temperature monitoring as part of the blood flow sensing, the progress of ablation can be monitored by temporarily switching mode selection switch 726 to a temperature sensing position several times during the ablation.



FIG. 8 shows another embodiment of a circuit 800 that can be used to distinguish between blood and non-blood tissue by sensing flow.


In this example, transducer elements 802a-802g (collectively 802, only seven called out in FIG. 8) may be resistive elements, for example formed from copper traces on a printed circuit board substrate, or resistive wires mounted on a structure. The ends of each transducer element 802 are electrically coupled to the ends of adjacent transducer elements 802 to form a connected grid or array 804. Each node (indicated in FIG. 8 by the markings A, B, C, D, E, F, G, H, and I) in the grid or array is electrically coupled to a respective control wire, collectively 806. The control wires 806 extend out of the human or animal body via a cable 808, which may, for example extend through a lumen of a catheter.


The control wires 806 may be coupled to respective ones of transducer selection switches 810a-810i (collectively 810) at a proximate end of a catheter. Each of the transducer selection switches 810 is controlled by a control system 812, which may, for example, take the form of a programmed general purpose computer, special purpose computer, applications specific integrated circuit (ASIC) or field programmable gate array (FPGA). The control system 812 applies signals to select between an adjustable current source 814a-814i (collectively 814) and ground 816 (only one called out in FIG. 8).


When a given transducer element 802 is to be used for blood flow sensing, the transducer selection switch 810 connected to the node A-I on one end of the given transducer element 802 is set to select the current source 814 and the transducer selection switch 810 connected to the node on the other end of the given transducer element 802 is configured to select ground 816. All nodes connected by a transducer element 802 to the node configured to select a current source 814 are also configured to select a current source 814. All nodes connected by a transducer element 802 to the node configured to select a ground are also configured to select ground 816. All of the connected current sources 814 are adjusted to deliver the same small voltage at the nodes A-I they are connected to. For example, if the transducer element 802e is to be used, then nodes B, D E, and H will be connected to current sources 814b, 814d, 814e, 814h, and nodes A, C, F, G, and I will be connected to ground 816. The connected current sources 814b, 814e, 814d, 814h will be adjusted so that the voltage at nodes B, E, D, and H will be the same. The control system 812 controls the voltage at the nodes, for example by:

    • selecting the desired node with a multiplexer 818;
    • measuring the voltage with an analog to digital converter (ADC) 820; and
    • adjusting the corresponding current source 814 to achieve the desired voltage.


In this configuration, the current through all transducer elements 802 connected to the given transducer element 802e will be zero. Therefore all current from the current source 814e connected to the given transducer element 802e will pass through the transducer element 802e. As both the voltage drop across and the current through the given transducer element 802e are known, the resistance can be determined and the corresponding temperature can be determined. Determination of the location of the openings or ports into the cavity (e.g., chamber or atrium) may be achieved by turning on all or at least some of transducer elements 802 sequentially, and determining the temperature by measuring a resistance of each of the transducer elements 802. The control system 812, or some other system, may produce a map of the temperature of the transducer elements 802, where the lower temperatures correspond to the openings or ports leading to veins or valves.


When a transducer element 802 is to be used for ablation, the transducer selection switch 810 connected to the node A-I on one end of the given transducer element 802 is set to select the current source 814 and the transducer selection switch 810 connected to the node A-I on the other end of the given transducer element 802 is configured to select a ground connection 816. All nodes A-I connected by a transducer element 802 to either end of the given transducer element 802 to be used for ablation are configured to select a current source 814. The current source 814 connected to the given transducer element 802 to be used for ablation is set to deliver sufficient power to the given transducer element 802 to raise its temperature to 50° C.-100° C., enough to cause non-blood tissue ablation. All of the other connected current sources 814 are adjusted to deliver current so that the voltages at the node A-I they are connected to is a percentage of the voltage at the node A-I connected to the given transducer element 802 being used for ablation. For example, if the transducer element 802e is to be used for ablation, then nodes B, C, D, E, H, and I will be connected to current sources 814b, 814c, 814d, 814e, 814h, 814i, and node A, F, and G will be connected to ground 816. The current source 814e connected to node E will be adjusted so that sufficient power is delivered to transducer element 802e to cause ablation. In doing so, a voltage will be generated at the node E. The current sources 814b, 814d, 814h connected to nodes B, D, and H are set to ensure the voltage at those nodes is, for example 66% of the voltage at node E. The current sources 814c, 814i connected to nodes C and I are set to ensure the voltages at those nodes is, for example 33% the voltage at node E. In doing do, the power delivered to all transducer elements 802 connected to nodes B, C, D, H, and I will be 11% of the power delivered to the given transducer element 802e, which is insufficient for ablation. It is possible to use different percentages for voltage values than specified herein.


While FIG. 8 shows one current source for each element, it is also possible to create a circuit that uses multiplexing to reduce the number of required current sources. Also, a circuit can be specified that uses voltage sources instead of current sources.


There are several ways to improve the accuracy in sensing the voltage drop across the transducer elements to improve accuracy of temperature measurement or flow sensing. One approach to achieve improved accuracy is to use four terminal sensing.



FIG. 6A shows a circuit 600a that implements four terminal sensing, according to one illustrated embodiment.


In FIG. 6A, a transducer element 602a is coupled to power leads 604a, 604b (collectively 604) to supply the current necessary to cause the transducer element 602a to heat sufficiently to be able to measure convective cooling. Measurement leads 606a, 606b (collectively 606) are used to measure the voltage across the transducer element 602a. Negligible current goes through measurement leads 606a, 606b and so there is no voltage drop over the length of the measurement leads 606.


In some configurations, being able to minimize the effect of lead resistance when measuring voltage across the transducer elements is possible without adding additional wires. FIG. 6B shows a circuit 600b that may implement such.


In temperature sensing or convective cooling sensing mode, leads 610a, 610b (collectively 610) are used to supply and sink the current necessary to cause transducer elements 612a-612e (collectively 612) to produce sufficient heat to be able to measure convective cooling. Leads 614a, 614b are used to measure the voltage across transducer element 612a. Leads 614b, 614c are used to measure the voltage across transducer element 612b. Leads 614c, 614d are used to measure the voltage across transducer element 612c. Leads 614d, 614e are used to measure the voltage across transducer element 612d. Leads 614e, 614f are used to measure the voltage across transducer element 612e. During ablation mode, leads 614a, 614b are used to supply the current to cause transducer element 612a to ablate the non-blood tissue, leads 614b, 614c are used to supply the current to cause the transducer element 612b to ablate, and so on.



FIG. 6C shows a circuit 600c according to another illustrated embodiment. The circuit 600c may minimize the effect of lead resistance when measuring voltage across the transducer elements without adding additional wires.


As an example, the transducer element 622a between nodes J and O is being used for temperature, flow, or convective cooling sensing. The leads connected to nodes J and O supply the current to the transducer element 622a between the nodes. This causes a measurable voltage drop across the transducer element 622a between nodes J and O. The leads attached to nodes B, D, E, F, I, K, N, P, S, T, U, W are used to sense voltage at the respective nodes. The control system to which the leads are attached is configured so that there is negligible current flow through these leads, and negligible voltage drop across the leads. The leads attached to nodes A, C, G, H, L, M, Q, R, V, and X are actively driven and drive the nodes to a particular voltage. The control system adjusts the voltages at nodes A, C, G, H, and L so that the voltage measured at nodes B, D, E, F, I, and K are all measured to be equal. When this state occurs, the current between nodes E and D, E and B, E and F is negligible and therefore, the current between nodes E and J must be negligible, and node E will be at the same potential as node J. The control system adjusts the voltages at nodes X, R, V, M, and Q so that the voltage measured at nodes W, S, T, U, N, and P are all measured to be equal. When this state occurs, the current between nodes S and T, T and W, T and U is negligible and therefore, the current between nodes T and O must be negligible, and node T will be at the same potential as node O. The voltage drop across the element between nodes J and O is therefore equal to the difference between the voltage at node E and the voltage at node T.



FIG. 9 shows an embodiment that reduces the number of control leads.



FIG. 9 shows a circuit 900 that includes a plurality of transducer elements 902a-902i (collectively 902, only nine called out in FIG. 9) which may form a one-, two-, or three-dimensional grid or array 904. A plurality of diodes 906a-906i (collectively 906, only nine called out in FIG. 9) or other non-linear devices or active devices are used to reduce the number of control leads 908. The leads 908 may be externally accessible from an exterior of a patient, for example via a cable 910 that extends through a lumen of a catheter or otherwise forms part of a catheter.


When this circuit 900 is not sensing or ablating, adjustable voltage sources 914a-914h (collectively 914, only eight called out in FIG. 9) are configured to reverse bias the diodes 906, so no current flows in the circuit 900. The circuit 900 may includes a plurality of current sensors 912a-912h (collectively 912), which couple signals indicative of sensed currents to a control system 916. In this example, the reverse biasing operation is achieved by setting voltage sources 914a-914d to positive voltage “h” and voltage sources 914e-914h to ground. When a transducer element 902 is to be used for flow sensing, temperature sensing, or ablation, the diode 906 that is in series with the given transducer element 902 is forward biased. This is achieved by setting the voltage source 914 that is connected to the given diode 906 to a positive voltage “g” that is greater than 0 and less than h, and setting the voltage source 914 that is connected to the given transducer element 902 to a positive voltage “f” which is greater than 0 and less than g and sufficient to forward bias the respective diode 906. For example, if the transducer element 902e is to be used for sensing or ablation, adjustable voltage source 914g should be set to g volts, adjustable voltage source 914b should be set to f volts, adjustable voltage sources 914a, 914c, 914d should be set to h volts, and adjustable voltage sources 914e, 914f, and 914h should be set to ground where 0<f<g<h. The particular values used for f, g, and h depend on such factors as the desired amount of heat from the transducer element 902 and the resistance of the transducer element 902. Since the forward voltage of a silicon diode changes about 2 mV/degC, the diodes 906 can also be used as temperature sensors.


In some embodiments, it is beneficial to ensure the entire medical treatment device is electrically insulated from the body. The reasons that this may be desirable are to prevent electrochemical activity from generating offset voltages, prevent leakage currents from affecting measurements and prevent gas bubble generation inside the blood stream.


Sensing Impedance Change


Measuring electrical impedance has been suggested as a way for determining when a catheter probe is in contact with the non-blood tissue of the heart wall. However, distinguishing non-blood tissue from blood using electrical impedance is problematic as the impedance is affected by many factors such as contact pressure and contact area. Also, the transducer element (e.g., electrode) may be in contact with many different materials, each of which has different impedance. However, using permittivity (also known as dielectric constant) measured over a range of frequencies can be used effectively to make the determination between blood and non-blood tissue.


As mentioned, material such as blood, muscle tissue, fat, fibrous material, and calcified tissue each has different impedance. However, in all the materials mentioned, except for blood (and other liquids such as urine) the permittivity drops with increasing frequency. For example, the conductivity of all those materials, including blood, stays nearly constant from DC to over 100 MHz. The permittivity of blood (and most other liquids in the body) is about the same at 1 KHz and 100 Khz, while in all other materials mentioned the dielectric constant drops by about a factor of 4, and typically by at least a factor of 10 between those two frequencies. Therefore, accurate discrimination between blood and non-blood tissue can be made by monitoring the ratio of the permittivity at 1 KHz to the value at 100 KHz. Table 1 and Table 2 show the change of Conductivity and Relative Permittivity with respect to frequency.









TABLE 1







Tissue Conductivity









Conductivity (S/m)












log10(Freq)
3
5
6
7
8















Blood
0.7
0.7
0.7
1
1.49


Fat
0.025
0.025
0.03
0.04
0.06


Muscle
0.4
0.4
0.4
0.4
0.75


Fibrous Material
0.24
0.24
0.24
0.29
0.33


Calcium
0.08
0.08
0.1
0.12
0.17


Vessel Wall
0.58
0.58
0.58
0.67
0.83
















TABLE 2







Tissue Relative Permittivity









Relative Permittivity












log10(Freq)
3
5
6
7
8















Blood
4100
4000
2000
300
75


Fat
20000
100
50
30
12


Muscle
400000
10000
8000
200
70


Fibrous Material
2000
500
50
5
3


Calcium
10500
500
250
70
30


Vessel Wall
100000
5000
4000
100
30










FIGS. 10A-10D show examples of different ways that transducer elements to sense permittivity may be constructed. FIGS. 10A-10D show examples of various transducer elements which may be constructed using flexible printed circuit board substrates and/or materials. The resulting transducer elements may be affixed to a structure similar to the expandable frame 208 (FIG. 2) made from a material such as Nitinol. Alternatively, the resulting transducer elements may include PCB substrates of such a thickness that the PCB substrates may form the frame itself. The transducer elements could also be constructed using discrete components.



FIG. 10A shows a flexible PCB substrate 1000a that carries permittivity sensor elements 1002 (only one called out in FIG. 10A) responsive to permittivity, ablation elements 1004 (only one called out in FIG. 10A) operable to ablate, and temperature sensor elements 1006 (only one called out in FIG. 10A) responsive to temperature. In the illustrated embodiment, the ablation elements 1004 and temperature sensor elements 1006 share some control leads 1008. Leads 1008 are coupled to a control system (not illustrated in FIG. 10B). It is also possible that each ablation elements 1004 and temperature sensor elements 1006 has separate control leads 1008 coupled to a control system (not illustrated in FIG. 10B).



FIG. 108 shows a flexible PCB substrate 1000b that carries combined permittivity sensor and ablation elements 1010 (only one called out in FIG. 10B) that both responsive to permittivity and are operable to ablate tissue. The PCB substrate 1000b also carries separate temperature sensor elements 1012 (only one called out in FIG. 10B) that are responsive to temperature. Leads 1114 are coupled to a control system (not illustrated in FIG. 10B).



FIG. 10C shows a flexible PCB substrate 1000c that carries combined permittivity and ablate elements 1016 (only one called out in FIG. 10C) that both are responsive to permittivity and are operable to ablate non-blood tissue. Each of the combined permittivity and ablate elements 1016 has a respective lead, collectively 1018, extending to a control system (not shown in FIG. 10C). An example of a circuit used to control and activate the combined permittivity and ablate elements 1016 is shown in FIG. 11.



FIG. 10D shows a flexible PCB substrate 1000d that carries combined permittivity sensor, temperature sensor and ablation elements 1020 that are responsive to permittivity, responsive to temperature and operable to ablate non-blood tissue. Each of the combined elements is coupled by a respective lead, collectively 1022, to a control system (not illustrated in FIG. 10D). Such an embodiment can be built using a printed circuit board with copper traces that do not have a surface insulation. The temperature sensing and ablation can be controlled as previously described in reference to FIG. 7. The permittivity sensing can be controlled as will be described with reference to FIG. 11.



FIG. 11 shows a circuit 1100 that can be used to distinguish blood from non-blood tissue by detecting the change in permittivity, according to one illustrated embodiment.


A transducer element 1102 carried on a PCB substrate 1104 is in physical contact with a bodily material 1106 (non-blood tissue or blood). The bodily material 1106 is electrically grounded to a same return path 1108 as the circuit 1100. Instead of a return path, a ground electrode adjacent to the transducer element (e.g., electrode) 1102 can be used. An alternate embodiment may be to use a balanced pair of electrodes with equal but opposite phase signals relative to ground. Such a configuration increases immunity to electrical noise. When frequency F1 or F2 is fed to transducer element 1102 from oscillators 1110a, 1110b via a resistor 1112 the phase shift of the signal caused by the dielectric constant of the bodily material 1106 can be measured by a phase meter. The permittivity is the tangent of the phase shift. For better noise immunity both the in-phase component and the out-of-phase, or quadrature, are measured (outputs 1114a, 1114b) then divided to determine the phase shift. The in-phase and out-of phase components are measured by multiplying the voltage signal on transducer element 1102 with the driving signal and with the driving signal phase shifted by 90 degrees using phase shifter 1116 and multipliers 1118. A selector 1119 may be used to selectively switch between coupling the frequencies F1, F2, or no frequency.


A pair of analog-to-digital converters (ADC) 1120 are used to digitize the results, after low pass filtering by capacitor 1122. If desired, the complete operation can be performed digitally by digitizing the signal from the transducer element 1102, since the highest frequency is relatively low. A separate circuit can be used for each transducer element 1102 or a selector 1124 (also known as multiplexer or analog switch) can connect the same circuit to multiple transducer elements 1102 in rapid succession. The time needed for an accurate measurement is typically several milliseconds; therefore even a large grid or array of transducer elements 1102 can be mapped quickly. A same lead 1126 can also be used to feed current for RF ablation using ablation energy source 1128 and a switch 1130. Alternatively a different power source, such as a DC current source, could be connected and provide a voltage and current for directly causing the transducer element 1102 to produce a sufficient amount of heat to cause ablation.


Sensing Force


Another method of distinguishing between non-blood tissue and blood is to measure a force being exerted inwardly on one or more transducer elements mounted or otherwise carried by an expandable frame (e.g., expandable frame 208 of FIG. 2). As an example of this approach, the transducer elements may take the form of an array of force sensors, for example force sensing pads. A polymeric piezoelectric material, such as PVDF, may be used as a force sensing element and two or more force sensing elements may be combined to form a force sensing grid. Such force sensing elements are already commercially available, such as Ktech part number MP-25-04-PL (from www.ktech.com). These PVDF based force sensing pads are very thin, flexible, have high output and are easy to integrate into a flexible printed circuit board. Liquids, such as blood, create very little resistive force when the expandable frame forces the force sensor transducer elements outward to the non-blood tissue that forms the interior surface of the cavity being mapped. The force sensor transducer elements located proximate to the openings or ports will be subject to less force than those proximate to the non-blood tissue. The differing force distribution across the force sensor transducer elements enables the location of the openings or ports to be determined.



FIGS. 12A-12C show examples of different ways the force sensor transducer elements may be constructed using flexible printed circuit board substrates. Force sensor transducer elements may be affixed to a structure similar to previously described expandable frames (e.g., expandable frame 208 of FIG. 1) made from a material such as Nitinol. Alternatively, the PCB substrate may be of such a thickness that the PCB substrate can be the frame itself. The transducer elements could also be constructed using discrete components.



FIG. 12A shows a flexible printed circuit board substrate 1200a that carries separate force sensor transducer elements 1202 (only one called out in FIG. 12A) responsive to force, temperature sensor transducer elements 1204 (only one called out in FIG. 12A) responsive to temperature, and ablation transducer elements 1206 (only one called out in FIG. 12A) operable to ablate non-blood tissue. The various transducer elements 1202, 1204, 1206 share a common ground 1208. The ablation and temperature sensor transducer elements 1206, 1204, respectively, share a common control lead 1210. Control leads 1210 are coupled to a control system (not shown in FIG. 12A). The preferred force sensor transducer element 1202 is a polymeric piezoelectric material. An example of a circuit that can be used to control and monitor such force sensor transducer elements 1202 is shown in FIG. 13.



FIG. 12B shows a flexible printed circuit board substrate 1200b that carries separate force sensor transducer elements 1222 (only one called out in FIG. 12B) responsive to force and elements with a combined temperature sensor and ablation transducer elements 1224 (only one called out in FIG. 12B). Each of the transducer elements 1222, 1224 has respective leads, collectively 1226, coupled to a control system (not shown in FIG. 12B). The combined temperature sensor and ablation transducer elements 1224 can be controlled in the same way as described for the embodiment of FIG. 7. The force sensor transducer element 1222 can be controlled and monitored as described herein with reference to FIG. 13.



FIG. 12C shows a flexible printed circuit board substrate 1200c that carries force sensor transducer elements 1232 (only one called out in FIG. 12C) responsive to force, and combined or integrated temperature sensor and ablation transducer elements 1234 (only one called out in FIG. 12C) responsive to temperature and operable to ablate non-blood tissue. The combined temperature sensor and ablation transducer elements 1234 are distinct from the force sensor transducer elements 1232. Each of the various types of transducer elements 1232, 1234 has respective leads, collectively 1236, coupled to a control system (not shown in FIG. 12C) possibly via a multiplexer (not shown in FIG. 12C). The combined temperature sensor and ablation transducer elements may be controlled in the same way as previously discussed with reference to FIG. 7.



FIG. 13 shows an embodiment of a circuit 1300 used to sense the forces the force sensor transducer elements (e.g., FIGS. 12A-12C) sense, according to one illustrated embodiment.


A force is exerted on a force sensor transducer element 1302 carried by a flexible PCB substrate 1304, by a bodily material 1306, for example blood or non-blood tissue.


A charge amplifier 1308 converts an output of the force sensor transducer element 1302 to a voltage which is digitized by an analog-to-digital (ADC) converter 1310. This voltage is proportional to the force exerted on the force sensor transducer element 1302 by the bodily material 1306, and the output may be indicative of a pressure. An ablation transducer element (e.g., electrode) can be used for temperature monitoring, as explained earlier, or a separate temperature sensor 1312 can be used. A capacitor 1314 can be used to isolate the RF from the DC current used for temperature sensing. Temperature sensing may be used by a temperature controller 1316 to control an ablation power source 1318 to cause an ablation transducer element 1320 to produce an appropriate amount of ablation (e.g., controlling time, temperature, current, power, etc.). A switch 1322 or valve may selectively couple the ablation power source 1318 to the ablation transducer element 1320.


When a polymeric piezoelectric material is used as the force sensor transducer element 1302, it is important to ensure the force sensor transducer element 1302 is sufficiently electrically insulated to eliminate any leakage current. A possible insulating material to use is silicone. Also, integrating an amplifier near the piezoelectric force sensor transducer element 1302 may improve the circuit performance and may make the circuit 1300 less susceptible to leakage current.


Although this circuit 1300 uses multiplexing via connectors 1330a, 1330b to measure the force exerted on the elements, it is also possible to forgo multiplexing and have a circuit dedicated for each element, or a combination of both techniques.


Note that the same piezoelectric sensing grid can also be used in alternate ways to differentiate non-blood tissue from blood. For example, it can be used as an ultrasonic transmitter and receiver to differentiate based on reflection or on damping coefficient.


Frame


The frame provides expansion and contraction capabilities for the component of the medical device (e.g., grid or array of transducer elements) used to distinguish between blood and non-blood tissue. The transducer elements used to sense a parameter or characteristic to distinguish between blood and non-blood tissue may be mounted or otherwise carried on a frame, or may form an integral component of the frame itself. The frame may be flexible enough to slide within a catheter sheath in order to be deployed percutaneously. FIG. 2, discussed previously, showed one embodiment of such a frame. Additional embodiments of frames are shown in FIGS. 14A, 14B, 15A, 15B, 15C, 16A and 16B.



FIG. 14A shows a frame 1400 made from a number of helical members 1402a, 1402b (collectively 1402) in an unexpanded configuration and positioned within a catheter sheath 1404 of a catheter 1408. FIG. 14B shows the frame 1400 extended outside of the catheter sheath 1404 and in an expanded configuration.


The helical members 1402 may be disposed about a shaft 1410. The helical members 1402 may be positioned between opposing stops 1412a, 1412b, which engage the ends of the helical members 1402 to cause expansion. While two helical members are shown, some embodiments may employ a greater or fewer number of helical members 1402.


The frame 1400 is expanded by retracting a shaft 1410. Retracting the shaft 1410 causes the midpoint of the helical members to be forced outward and move toward the interior surface of the cavity in which the frame is positioned. FIG. 14B shows that some of the helical members 1402 are oriented in a clockwise direction and others are oriented in a counter clockwise direction. The opposing directions cause the helical members 1402a, 1402b to cross over and form a grid.


The helical members 1402 may be constructed of many different types of material including solid wire (such as stainless steel), hollow tube, carbon fiber, or a flexible PCB with a fibreglass or Nitinol backing. The helical members 1402 may form an integral component of the sensing and ablation transducer elements. FIG. 4 provided several example of how elements could be constructed from solid wire, hollow tube, carbon fiber, or flexible PCB. When the transducer elements form an integral component of the frame, the material to be used for the frame requires proper mechanical and electrical properties. If the device is distinguishing between blood and non-blood tissue using flow sensing, the material used for the helical members 1402 preferably has a significant change in resistance with temperature that is independent of helical members 1402 deformation. Also, a resistance of several ohms per centimetre or higher is preferable as it will reduce the amount of current needed to heat the transducer element. The helical members 1402 may also act as a support for a secondary assembly that carries the sensing and ablation transducer elements. An example of this is a stainless steel or Nitinol structure used to expand transducer elements made with a flexible PCB substrate.



FIGS. 15A-15C show a frame 1500, according to another illustrated embodiment.


The frame 1500 includes a single helical member 1502, a plurality of ribs 1504, and a shaft 1506, oriented approximately parallel to a longitudinal axis of a catheter 1508. The sensor and ablation transducer elements are located along the helical member 1502 and ribs 1504.



FIG. 15A shows the frame 1500 in its unexpanded or contracted configuration, positioned within a catheter sheath 1510 of the catheter 1508. In the unexpanded or contracted configuration, the ribs 1504 are compressed against the shaft 1506 and the single helical member 1502 is wound around the ribs 1504. The catheter sheath 1510 is inserted partially into the lumen, cavity, chamber or atrium that the device is to operate in. The frame 1500 is then pushed out of the sheath 1510 into the chamber and then expanded.



FIG. 15B shows the frame 1500 in a partially expanded configuration. The frame 1500 is expanded by first unwinding the helical member 1502. The shaft 1506 is rotated, which causes the helical member 1502 to unwind and expand outward from the shaft 1506.



FIG. 15C shows the frame 1500 in a fully expanded configuration. The frame 1500 is fully expanded by retracting the shaft 1506, which causes the ribs 1504 to bow outwards and move both the helical member 1502 and ribs 1504 to be proximate to the non-blood tissue that forms the interior surface of the chamber. The ribs 1504 and helical member 1502 may only be physically attached at the proximal and distal ends of the ribs 1504 and helical member 1502, or the ribs 1504 may have loops spaced along their length through which the helical member 1502 slides.


There are several variations on the example shown in FIGS. 15A-15C. These include a frame in which the helical member is inside the ribs, and pushes the ribs outward. Alternatively, a frame may include a helical member that is positioned inside the ribs, and the ribs are only attached at the proximal or distal end.


The same principles regarding construction and composition of the ribs described for the frame 1400 of FIGS. 14A and 14B may be applied to the frame 1500 of FIGS. 15A-15C.



FIGS. 16A and 16B show an embodiment a frame 1600 made using one or more inflatable members 1602. The particular inflatable member 1602 shown is approximately spherical in shape, although it is possible to construct a frame using inflatable members that are oblong as well.



FIG. 16A shows the frame 1600 in an inflated or expanded configuration. FIG. 16B shows a cross section of the frame 1600. The preferred method of expanding this frame 1600 is to inflate via one or more ports 1604 with a fluid. A fluid, such as saline, that is not dangerous if inadvertently released into the body may be particularly suitable. The port 1604 may be fluidly communicatively coupled to source of fluid, for example via one or more lumens of a catheter 1606. The source of fluid may be pressurized. The inflatable member 1602 may be folded inside a catheter sheath 1608 for percutaneous or intravascular delivery. The inflatable member 1602 may be withdrawn or pushed from the catheter sheath 1608 when in a desired position in the bodily organ.


This inflatable member may have one or more passages, collectively 1610, (only three called out in FIGS. 16A and 16B) opening to the exterior surface 1612. The passages 1610 may provide fluid communication through the inflatable member 1602. For example, the passages 1610 may connect to a hollow interior cavity 1614. These passages 1610 allow blood to flow through the frame 1600 even when the frame 1600 is inflated sufficiently to be in contact with the interior surface of the lumen, cavity, chamber or atrium in which the frame 1600 is located. Thus, blood may flow from a downstream side or position, to and open stream side or position, relative to the position of the frame 1600, even when inflated and in the expanded configuration. Such advantageously prevents occlusion.


An advantageous design feature when building an inflatable member that has interior structures, such as blood flow passages 1610 or an inner cavity 1614 is that the walls that form those interior structures should be reinforced to prevent the wall from collapsing or buckling. Such reinforcement can be accomplished in variety of ways. For example, by creating the inner walls using much thicker material, creating ribbed walls with alternating thinner or thicker sections, collectively 1616, (only three called out in FIG. 16B), or reinforcing the walls with spring like wires.


An inflatable frame 1600 as described may be created using a material such as latex. This device may be used as a supporting frame for elements, for example constructed using flexible printed circuit boards.


Joint Assembly


Several of the frames discussed in the preceding section employ joints where transducer elements cross over one another. FIGS. 17A-17E and FIGS. 18A-18B show several examples of different structures that can be used.



FIG. 17A shows several strips 1702a-1702c (collectively 1702) of flexible printed circuit board substrate at different orientations to one another. Such strips 1702 may be used to build the ribs, struts, or frame members mentioned previously. Where the strips 1702 cross, they may be joined by a hinge 1704a, 1704b (collectively 1704) that attaches both strips 1702. The hinge 1704 may, for example extend through both strips 1702. The 1702 strips are still able to swivel around the hinge point. The preferred place to join the strips 1702 is at the connecting points between transducer elements 1708a, 1708b (collectively 1708, only two called out in FIG. 17A). If the transducer elements 1708 are designed to share leads, the hinge can be used to electrically connect the transducer elements 1708 that have an end coincident with the joint. Alternatively the transducer elements 1708 may be electrically insulated from the hinge 1704 with no electrical contact points between the strips 1702. The transducer elements 1708 between the hinges 1704 may be used to distinguish between blood and non-blood tissue and/or to ablate. Leads may extend along each strip 1702 back to the catheter (not shown in FIG. 17A) and to a control system (not shown in FIG. 17A).



FIG. 17B shows several strands 1722a-1722c (collectively 1722) of carbon fiber at different orientations to one another. Such strands 1722 may be used to build the ribs, struts, or frame members mentioned previously. Where the strands 1722 cross, the carbon fiber strands 1722 are pinched or crimped 1724a, 1724b (collectively 1724) together, for example by means of a crimping mechanism. The crimping mechanism may be made from materials such as carbon fibre, carbon paste (cured by heating) metal, or glue. Pinching the carbon fibre together at the joint enables the strands to swivel about the joint. The carbon fibre between each connecting point can be used as a transducer element 1726 (only one called out in FIG. 17B) to sense flow, sense temperature and/or to ablate. A lead 1728 (only one called out in FIG. 17B) can be connected at each joint to control the transducer elements 1726 as shown by the circuit 800 of FIG. 8.



FIG. 17C shows several wires or hollow tubes 1730a-1730b (collectively 1730) made of material such as stainless steel or Nitinol, at different orientations from one another. Such wires or tubes 1730 may be used to build the ribs, struts, or frame members mentioned previously. Where the wires or tubes 1730 cross, they are connected at joints or connection points 1732a, 1732b (collectively 1732) for example by being fused together using spot or laser welding. The wire or tube between each connecting point can be used as a transducer element, collectively 1734 (only one called out in FIG. 17C), to sense flow, sense temperature and/or to ablate. A lead, collectively 1736 (only one called out in FIG. 17C), can be connected at each joint or connection point 1732 to control the transducer elements 1734 as shown by the circuit in FIG. 8.



FIG. 17D shows several strips 1742a-1742c (collectively 1742) of flexible printed circuit board substrate at different orientations to one another. Such strips 1742 may be used to build the ribs, struts, or frame members mentioned previously. Where the strips 1742 cross 1744a, 1744b (collectively 1744), they are not mechanically joined, but allowed to slide over top of each other. Since a fixed hinge point does not exist in the configuration, it is necessary to be able to determine where the strips 1742 cross when the frame is in the expanded configuration inside a body lumen, cavity, chamber or atrium in order to properly determine the location of openings or ports of the lumen, cavity, chamber or atrium. One method of doing this is to make use of the heating and temperature sensing capabilities of the transducer elements 1746 (only one called out in FIG. 17D). Each transducer element 1746 should be heated slightly in turn (such as several degrees above blood temperature) while other transducer elements 1746 are sensing temperature. If the transducer element 1746 being heated is located at a crossing point, a different transducer element 1746 sensing temperature, but also located at the same crossing point will sense a temperature increase. All or most pairs of transducer elements 1746 that cross may be determined using such an approach



FIG. 17E shows a flexible printed circuit board substrate 1752 in a leaf shape. Such a PCB substrate 1752 is used to cover one portion of the interior surface of the body cavity. Multiple such PCB substrates may be joined together as shown in FIG. 2, to cover at least a significant portion of the surface of a lumen, cavity, chamber or atrium. These PCB substrates may surround a frame that is used to push them outward and proximate to the surface. The PCB substrates may overlap. Overlapping transducer elements 1754a, 1754b (collectively 1754, only two called out in FIG. 17E) may be determined using the method described for the embodiment of FIG. 17D.



FIG. 18A shows a frame 1800 formed from metal strips 1802a-1802c (collectively 1802) formed to have flexure points 1804. Such strips 1802 may be used to build the ribs, struts, or frame members mentioned previously. The ribs, struts, or frames have crossing points 1806a, 1806b (collectively 1806). At the crossing points 1806 the metal strips 1802 are fused together using spot welding. The metal strips 1802 are formed to have a flexure 1804 on either side of the crossing point 1806. The flexure 1804 enables the strips 1802 to bend which may be beneficial for the expansion and contraction of the frame 1800. A portion of the strip 1802 between each connecting or crossing point 1806 can be used as a transducer element 1808 (only one called out in FIG. 18A) to sense flow, sense temperature and/or to ablate non-blood tissue. A lead 1810 (only one called out in FIG. 18A) can be connected at each joint to control the transducer elements 1808 as shown by the circuit in FIG. 8.



FIG. 18B shows a frame 1820 formed from metal strips 1822a-1822d (collectively 1822) formed to have slots 1824 (only one illustrated). Such strips 1822 may be used to build the ribs, struts, or frame members mentioned previously. The ribs, struts, or frames have crossing points 1826a-1826d (collectively 1826). At the crossing point 1826 of two strips 1822, one of the strips has a slot 1824 and the other strip 1822 slides through the slot 1824. The slot 1824 may be formed in a strip 1822 by joining two thin strips 1828a, 1828b by spot welds 1830 (only two called out in FIG. 18B). It is possible to connect the control leads 1832 to the spot welds 1830 which are located between the crossing points 1826 and use the portions of the strips 1822 between each connecting or crossing point 1826 as a transducer element to sense flow, sense temperature and/or ablate non-blood tissue. However, this method will require approximately 40% more wires than connecting the control leads at the crossing points.


The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety. Aspects of the invention can be modified, if necessary, to employ systems, circuits and concepts of the various patents, applications and publications to provide yet further embodiments of the invention.


These and other changes can be made to the invention in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the invention to the specific embodiments disclosed in the specification and the claims, but should be construed to include all medical treatment devices in accordance with the claims. Accordingly, the invention is not limited by the disclosure, but instead its scope is to be determined entirely by the following claims.

Claims
  • 1. A medical system comprising: a catheter shaft;a meshed structure coupled to the catheter shaft and comprising a plurality of segments, the meshed structure including a plurality of vertices, each vertex of the plurality of vertices being where at least two segments of the plurality of segments converge, and a first vertex of the plurality of vertices coupled to a second vertex of the plurality of vertices at least by way of overlapping portions of the meshed structure;a sensor; anda control line coupled to the sensor, a coupling location of the control line located at a location where the first vertex is coupled to the second vertex.
  • 2. The medical system of claim 1, wherein at least one segment of the at least two segments converging at the first vertex is electrically insulated from at least one segment of the at least two segments converging at the second vertex.
  • 3. The medical system of claim 1, wherein at least a first segment of the at least two segments converging at the first vertex is a metallic segment, and at least a second segment of the at least two segments converging at the second vertex is a metallic segment.
  • 4. The medical system of claim 1, wherein at least a first segment of the at least two segments converging at the first vertex is selectively operable to deliver tissue ablative energy.
  • 5. The medical system of claim 4, wherein at least a second segment of the at least two segments converging at the second vertex is selectively operable to deliver tissue ablative energy.
  • 6. The medical system of claim 5, wherein the first segment of the at least two segments converging at the first vertex is configured to deliver tissue ablative energy independently of the second segment of the at least two segments converging at the second vertex.
  • 7. The medical system of claim 1, wherein at least a first segment of the at least two segments converging at the first vertex is physically coupled at least by way of a connector to at least a second segment of the at least two segments converging at the second vertex at a location of the overlapping portions of the meshed structure.
  • 8. The medical system of claim 1, wherein the first vertex is physically coupled to the second vertex via at least a connector.
  • 9. The medical system of claim 8, wherein the connector extends through at least a first segment of the at least two segments converging at the first vertex and at least a second segment of the at least two segments converging at the second vertex.
  • 10. The medical system of claim 1, wherein at least a first segment of the at least two segments converging at the first vertex is physically coupled at least by way of a connector to at least a second segment of the at least two segments converging at the second vertex to swivel with respect to one another.
  • 11. The medical system of claim 1, wherein the first vertex is physically coupled via at least a connector to the second vertex, the connector configured to allow at least a first segment of the at least two segments converging at the first vertex to swivel with respect to at least a second segment of the at least two segments converging at the second vertex.
  • 12. The medical system of claim 1, wherein at least a first segment of the at least two segments converging at the first vertex is fixedly coupled to at least a second segment of the at least two segments converging at the second vertex at a location of the overlapping portions of the meshed structure.
  • 13. The medical system of claim 1, wherein at least a first segment of the at least two segments converging at the first vertex overlaps at least a second segment of the at least two segments converging at the second vertex.
  • 14. The medical system of claim 1, wherein the sensor is configured to at least sense temperature.
  • 15. The medical system of claim 1, wherein the sensor is configured to at least sense electrical potential of tissue that forms a heart wall.
  • 16. The medical system of claim 1, wherein the sensor is configured to at least sense a tissue characteristic.
  • 17. The medical system of claim 1, wherein the meshed structure is moveable from a contracted configuration and an expanded configuration, the meshed structure sized to fit within a catheter sheath in the contracted configuration.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/658,820, filed Oct. 21, 2019, now U.S. Pat. No. 11,331,141, issued May 17, 2022, which is a continuation of U.S. patent application Ser. No. 15/784,647, filed Oct. 16, 2017, now U.S. Pat. No. 10,828,096, issued Nov. 10, 2020, which is a continuation of U.S. patent application Ser. No. 14/713,190, filed May 15, 2015, now U.S. Pat. No. 9,820,810, issued Nov. 21, 2017, which is a continuation of U.S. patent application Ser. No. 14/564,463, filed Dec. 9, 2014, now U.S. Pat. No. 9,877,779, issued Jan. 30, 2018, which is a continuation of U.S. patent application Ser. No. 13/070,215, filed Mar. 23, 2011, now U.S. Pat. No. 8,932,287, issued Jan. 13, 2015, which is a continuation of U.S. patent application Ser. No. 11/941,819, filed Nov. 16, 2007, now U.S. Pat. No. 8,906,011, issued Dec. 9, 2014, wherein the entire disclosure of each of the applications cited in this sentence is hereby incorporated herein by reference.

US Referenced Citations (743)
Number Name Date Kind
4114202 Roy et al. Sep 1978 A
4164046 Cooley Aug 1979 A
4225148 Andersson Sep 1980 A
4240441 Khalil Dec 1980 A
4263680 Reul et al. Apr 1981 A
4273128 Lary Jun 1981 A
4411266 Cosman Oct 1983 A
4490859 Black et al. Jan 1985 A
4543090 McCoy Sep 1985 A
4576182 Normann Mar 1986 A
4699147 Chilson et al. Oct 1987 A
4770187 Lash et al. Sep 1988 A
4787369 Allred, III et al. Nov 1988 A
4794912 Lia Jan 1989 A
4850957 Summers Jul 1989 A
4887613 Farr et al. Dec 1989 A
4890602 Hake Jan 1990 A
4890612 Kensey Jan 1990 A
4893613 Hake Jan 1990 A
4895166 Farr et al. Jan 1990 A
4905667 Foerster et al. Mar 1990 A
4921499 Hoffman et al. May 1990 A
4940064 Desai Jul 1990 A
4942788 Farr et al. Jul 1990 A
4979514 Sekii et al. Dec 1990 A
4998933 Eggers et al. Mar 1991 A
5026384 Farr et al. Jun 1991 A
5047047 Yoon Sep 1991 A
5122137 Lennox Jun 1992 A
5127902 Fischell Jul 1992 A
5153151 Aitken Oct 1992 A
5156151 Imran Oct 1992 A
5174299 Nelson Dec 1992 A
5176693 Pannek, Jr. Jan 1993 A
5178620 Eggers et al. Jan 1993 A
5192291 Pannek, Jr. Mar 1993 A
5195505 Josefsen Mar 1993 A
5201316 Pomeranz et al. Apr 1993 A
5228442 Imran Jul 1993 A
5242386 Holzer Sep 1993 A
5245987 Redmond et al. Sep 1993 A
5255679 Imran Oct 1993 A
5279299 Imran Jan 1994 A
5293869 Edwards et al. Mar 1994 A
5297549 Beatty et al. Mar 1994 A
5309910 Edwards et al. May 1994 A
5311866 Kagan May 1994 A
5312435 Nash et al. May 1994 A
5317952 Immega Jun 1994 A
5324284 Imran Jun 1994 A
5327889 Imran Jul 1994 A
5341807 Nardella Aug 1994 A
5345936 Pomeranz Sep 1994 A
5351551 Drubetsky Oct 1994 A
5351679 Mayzels et al. Oct 1994 A
5366443 Eggers et al. Nov 1994 A
5370679 Atlee, III Dec 1994 A
5379773 Hornsby Jan 1995 A
5397321 Houser et al. Mar 1995 A
5419767 Eggers et al. May 1995 A
5450860 O'Connor Sep 1995 A
5456254 Pietroski et al. Oct 1995 A
5462545 Wang Oct 1995 A
5465717 Imran et al. Nov 1995 A
5478353 Yoon Dec 1995 A
5485849 Panescu et al. Jan 1996 A
5496267 Drasler et al. Mar 1996 A
5496330 Bates Mar 1996 A
5499981 Kordis Mar 1996 A
5531760 Alwafaie Jul 1996 A
5545193 Fleischman et al. Aug 1996 A
5549661 Kordis et al. Aug 1996 A
5555883 Avitall Sep 1996 A
5557967 Renger Sep 1996 A
5575810 Swanson et al. Nov 1996 A
5593424 Northrup, III Jan 1997 A
5598848 Swanson et al. Feb 1997 A
5599345 Edwards et al. Feb 1997 A
5620481 Desai et al. Apr 1997 A
5630813 Kieturakis May 1997 A
5636634 Kordis Jun 1997 A
5637090 McGee et al. Jun 1997 A
5662587 Grundfest et al. Sep 1997 A
5681308 Edwards et al. Oct 1997 A
5681336 Clement et al. Oct 1997 A
5687723 Avitall Nov 1997 A
5687737 Branham et al. Nov 1997 A
5697285 Nappl et al. Dec 1997 A
5704914 Stocking Jan 1998 A
5713896 Nardella Feb 1998 A
5713942 Stern et al. Feb 1998 A
5716397 Myers Feb 1998 A
5720726 Marcadis et al. Feb 1998 A
5728114 Evans et al. Mar 1998 A
5730127 Avitall Mar 1998 A
5738096 Ben-Haim Apr 1998 A
5762066 Law et al. Jun 1998 A
5769846 Edwards et al. Jun 1998 A
5782239 Webster, Jr. Jul 1998 A
5782879 Rosborough et al. Jul 1998 A
5800495 Machek et al. Sep 1998 A
5823189 Kordis Oct 1998 A
5824066 Gross Oct 1998 A
5831159 Renger Nov 1998 A
5836947 Fleischman et al. Nov 1998 A
5836990 Li Nov 1998 A
5853422 Huebsch et al. Dec 1998 A
5868743 Saul Feb 1999 A
5868755 Kanner et al. Feb 1999 A
5876343 Teo Mar 1999 A
5879295 Li et al. Mar 1999 A
5881727 Edwards Mar 1999 A
5885278 Fleischman Mar 1999 A
5891136 McGee et al. Apr 1999 A
5893847 Kordis Apr 1999 A
5904711 Flom et al. May 1999 A
5916163 Panescu et al. Jun 1999 A
5919207 Taheri Jul 1999 A
5921924 Avitall Jul 1999 A
5935075 Casscells et al. Aug 1999 A
5935079 Swanson et al. Aug 1999 A
5941251 Panescu et al. Aug 1999 A
5944715 Goble et al. Aug 1999 A
5961440 Schweich, Jr. et al. Oct 1999 A
5968040 Swanson et al. Oct 1999 A
5984950 Cragg et al. Nov 1999 A
6001069 Tachibana et al. Dec 1999 A
6001093 Swanson et al. Dec 1999 A
6014581 Whayne et al. Jan 2000 A
6023638 Swanson Feb 2000 A
6030382 Fleischman et al. Feb 2000 A
6036689 Tu et al. Mar 2000 A
6063082 DeVore et al. May 2000 A
6071282 Fleischman Jun 2000 A
6104944 Martinelli Aug 2000 A
6106460 Panescu Aug 2000 A
6106522 Fleischman et al. Aug 2000 A
6119030 Morency Sep 2000 A
6123702 Swanson et al. Sep 2000 A
6138043 Avitall Oct 2000 A
6142993 Whayne et al. Nov 2000 A
6156046 Passafaro et al. Dec 2000 A
6210432 Solem et al. Apr 2001 B1
6216043 Swanson et al. Apr 2001 B1
6217573 Webster Apr 2001 B1
6240307 Beatty May 2001 B1
6241747 Ruff Jun 2001 B1
6245064 Lesh et al. Jun 2001 B1
6248124 Pedros et al. Jun 2001 B1
6254598 Edwards Jul 2001 B1
6258258 Sartori et al. Jul 2001 B1
6266550 Selmon et al. Jul 2001 B1
6292695 Webster, Jr. et al. Sep 2001 B1
6304769 Arenson et al. Oct 2001 B1
6306135 Ellman et al. Oct 2001 B1
6308091 Avitall Oct 2001 B1
6319249 Tollner Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6325797 Stewart et al. Dec 2001 B1
6330478 Lee et al. Dec 2001 B1
6346105 Tu et al. Feb 2002 B1
6350263 Wetzig et al. Feb 2002 B1
6358258 Arcia et al. Mar 2002 B1
6383151 Diederich et al. May 2002 B1
6389311 Whayne et al. May 2002 B1
6391024 Sun et al. May 2002 B1
6391048 Ginn et al. May 2002 B1
6391054 Carpentier et al. May 2002 B2
6402781 Langberg et al. Jun 2002 B1
6428537 Swanson Aug 2002 B1
6436052 Nikolic et al. Aug 2002 B1
6471700 Burbank et al. Oct 2002 B1
6475223 Werp et al. Nov 2002 B1
6485409 Voloshin et al. Nov 2002 B1
6485482 Belef Nov 2002 B1
6485489 Teirstein et al. Nov 2002 B2
6506210 Kanner Jan 2003 B1
6514249 Maguire et al. Feb 2003 B1
6517534 McGovern Feb 2003 B1
6529756 Phan et al. Mar 2003 B1
6537198 Vidlund et al. Mar 2003 B1
6537314 Langberg et al. Mar 2003 B2
6540670 Hirata et al. Apr 2003 B1
6551310 Ganz et al. Apr 2003 B1
6551312 Zhang et al. Apr 2003 B2
6558378 Sherman et al. May 2003 B2
6569160 Goldin et al. May 2003 B1
6569198 Wilson et al. May 2003 B1
6575971 Hauck et al. Jun 2003 B2
6589208 Ewers et al. Jul 2003 B2
6616684 Mdlund et al. Sep 2003 B1
6626930 Allen et al. Sep 2003 B1
6632238 Ginn et al. Oct 2003 B2
6635056 Kadhiresan et al. Oct 2003 B2
6640119 Budd et al. Oct 2003 B1
6652515 Maguire et al. Nov 2003 B1
6652517 Hall et al. Nov 2003 B1
6662034 Segner et al. Dec 2003 B2
6666862 Jain et al. Dec 2003 B2
D484979 Fontaine Jan 2004 S
6704590 Haldeman Mar 2004 B2
6723038 Schroeder et al. Apr 2004 B1
6725085 Schwartzman et al. Apr 2004 B2
6726716 Marquez Apr 2004 B2
6733499 Scheib May 2004 B2
6735465 Panescu May 2004 B2
6738655 Sen et al. May 2004 B1
6760616 Hoey et al. Jul 2004 B2
6763836 Tasto et al. Jul 2004 B2
6773433 Stewart et al. Aug 2004 B2
6780197 Roe et al. Aug 2004 B2
6788969 Dupree et al. Sep 2004 B2
6795721 Coleman et al. Sep 2004 B2
6797001 Mathis et al. Sep 2004 B2
6800090 Alferness et al. Oct 2004 B2
6824562 Mathis et al. Nov 2004 B2
6837886 Collins Jan 2005 B2
6852076 Nikolic et al. Feb 2005 B2
6855143 Davison et al. Feb 2005 B2
6890353 Cohn et al. May 2005 B2
6892091 Ben-Haim et al. May 2005 B1
6899674 Viebach et al. May 2005 B2
6899709 Lehmann et al. May 2005 B2
6907297 Wellman et al. Jun 2005 B2
6908478 Alferness et al. Jun 2005 B2
6913576 Bowman Jul 2005 B2
6918903 Bass Jul 2005 B2
6926669 Stewart et al. Aug 2005 B1
6936047 Nasab et al. Aug 2005 B2
6942657 Sinofsky et al. Sep 2005 B2
6949122 Adams et al. Sep 2005 B2
6955640 Sanders et al. Oct 2005 B2
6960206 Keane Nov 2005 B2
6960229 Mathis et al. Nov 2005 B2
6966908 Maguire et al. Nov 2005 B2
6986775 Morales et al. Jan 2006 B2
6989010 Francischelli et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6994093 Murphy et al. Feb 2006 B2
6997925 Maguire et al. Feb 2006 B2
6997951 Solem et al. Feb 2006 B2
7001383 Keidar Feb 2006 B2
7003342 Plaza Feb 2006 B2
7025776 Houser et al. Apr 2006 B1
7044135 Lesh May 2006 B2
7048734 Fleischman et al. May 2006 B1
7050848 Hoey et al. May 2006 B2
7052487 Cohn et al. May 2006 B2
7068867 Adoram et al. Jun 2006 B2
7141019 Pearlman Nov 2006 B2
7144363 Pai et al. Dec 2006 B2
7166127 Spence et al. Jan 2007 B2
7174201 Govari et al. Feb 2007 B2
7177677 Kaula et al. Feb 2007 B2
7186210 Feld et al. Mar 2007 B2
7187964 Khoury Mar 2007 B2
7189202 Lau et al. Mar 2007 B2
7194294 Panescu et al. Mar 2007 B2
7198635 Danek et al. Apr 2007 B2
7252664 Nasab et al. Aug 2007 B2
7255695 Falwell Aug 2007 B2
7276044 Ferry et al. Oct 2007 B2
7279007 Nikolic et al. Oct 2007 B2
7282030 Frei et al. Oct 2007 B2
7300435 Wham et al. Nov 2007 B2
7303526 Sharkey et al. Dec 2007 B2
7311705 Sra Dec 2007 B2
7317950 Lee Jan 2008 B2
7335196 Swanson et al. Feb 2008 B2
7340307 Maguire et al. Mar 2008 B2
7468062 Oral et al. Dec 2008 B2
7481808 Koyfman et al. Jan 2009 B2
7496394 Ahmed et al. Feb 2009 B2
7507252 Lashinski et al. Mar 2009 B2
7530980 Hooven May 2009 B2
7575566 Scheib Aug 2009 B2
7593760 Rodriguez et al. Sep 2009 B2
7610078 Willis Oct 2009 B2
7633502 Willis et al. Dec 2009 B2
7660452 Zwirn et al. Feb 2010 B2
7736388 Goldfarb et al. Jun 2010 B2
7738967 Salo Jun 2010 B2
7826881 Beatty et al. Nov 2010 B1
8012149 Jackson Sep 2011 B2
8097926 De Graff et al. Jan 2012 B2
8103338 Harlev et al. Jan 2012 B2
D654588 Taube et al. Feb 2012 S
8118853 Grewe Feb 2012 B2
8147486 Honour et al. Apr 2012 B2
8150499 Gelbart et al. Apr 2012 B2
D660967 Braido et al. May 2012 S
8200308 Zhang et al. Jun 2012 B2
8216216 Warnking et al. Jul 2012 B2
8216228 Pachon Mateos et al. Jul 2012 B2
8221411 Francischelli et al. Jul 2012 B2
8224432 Macadam et al. Jul 2012 B2
8326419 Rosenberg et al. Dec 2012 B2
8352019 Starks Jan 2013 B2
8386057 Flach et al. Feb 2013 B2
8398623 Warnking et al. Mar 2013 B2
8398631 Ganz Mar 2013 B2
8401645 Rosenberg et al. Mar 2013 B2
8414508 Thapliyal et al. Apr 2013 B2
8442613 Kim et al. May 2013 B2
8442625 Markowitz et al. May 2013 B2
8457371 Markowitz et al. Jun 2013 B2
8463368 Harlev et al. Jun 2013 B2
8486063 Werneth et al. Jul 2013 B2
8500731 Byrd et al. Aug 2013 B2
8532734 Markowitz et al. Sep 2013 B2
8538501 Venkatachalam et al. Sep 2013 B2
8562559 Bishop Oct 2013 B2
8571647 Harlev et al. Oct 2013 B2
8615287 Harlev et al. Dec 2013 B2
8617156 Werneth et al. Dec 2013 B2
8617228 Wittenberger et al. Dec 2013 B2
8657814 Werneth et al. Feb 2014 B2
8663120 Markowitz et al. Mar 2014 B2
8706260 Stewart et al. Apr 2014 B2
8712550 Grunewald Apr 2014 B2
8725240 Harlev et al. May 2014 B2
8771267 Kunis et al. Jul 2014 B2
8831701 Markowitz et al. Sep 2014 B2
8834461 Werneth et al. Sep 2014 B2
8849384 Greenspan Sep 2014 B2
8864745 Ciavarella Oct 2014 B2
D717954 Hjelle et al. Nov 2014 S
8897516 Turgeman Nov 2014 B2
8920411 Gelbart et al. Dec 2014 B2
8926605 McCarthy et al. Jan 2015 B2
8932284 McCarthy et al. Jan 2015 B2
8939970 Stone et al. Jan 2015 B2
8961506 McCarthy et al. Feb 2015 B2
9033893 Spector May 2015 B2
9037259 Mathur May 2015 B2
9044245 Condie et al. Jun 2015 B2
9044254 Ladtkow et al. Jun 2015 B2
9095350 Condie et al. Aug 2015 B2
9101333 Schwartz Aug 2015 B2
9101365 Highsmith Aug 2015 B2
9107599 Harlev et al. Aug 2015 B2
9108052 Jarrard Aug 2015 B2
9119633 Gelbart et al. Sep 2015 B2
9119634 Gelbart et al. Sep 2015 B2
9179860 Markowitz et al. Nov 2015 B2
9179972 Olson Nov 2015 B2
9198713 Wallace et al. Dec 2015 B2
9204935 Hauck et al. Dec 2015 B2
9265434 Merschon et al. Feb 2016 B2
9277872 Harlev et al. Mar 2016 B2
9277960 Weinkam et al. Mar 2016 B2
9282910 Narayan et al. Mar 2016 B2
9332920 Thakur et al. May 2016 B2
9345540 Mallin et al. May 2016 B2
9398862 Harlev et al. Jul 2016 B2
9408544 Laughner et al. Aug 2016 B2
9433465 Gliner et al. Sep 2016 B2
9439578 Thakur et al. Sep 2016 B2
9456759 Lian et al. Oct 2016 B2
9474486 Eliason et al. Oct 2016 B2
9474491 Li et al. Oct 2016 B2
9486272 Bonyak et al. Nov 2016 B2
9504518 Condie et al. Nov 2016 B2
9522035 Highsmith Dec 2016 B2
9526568 Ohri et al. Dec 2016 B2
9532725 Laughner et al. Jan 2017 B2
9532828 Condie et al. Jan 2017 B2
9554718 Bar-Tal et al. Jan 2017 B2
9554847 Govari et al. Jan 2017 B2
9572620 Ryu et al. Feb 2017 B2
9579064 Kovtun et al. Feb 2017 B2
9603651 Ghosh Mar 2017 B2
9603661 Gelbart et al. Mar 2017 B2
9610045 Du et al. Apr 2017 B2
9622806 Mihalik Apr 2017 B2
9629567 Porath et al. Apr 2017 B2
9636032 Thakur et al. May 2017 B2
9655535 Narayan et al. May 2017 B2
9662033 Severino May 2017 B2
9693699 Spector et al. Jul 2017 B2
9713730 Mathur et al. Jul 2017 B2
9730600 Thakur et al. Aug 2017 B2
9730603 Laughner et al. Aug 2017 B2
9737227 Thakur et al. Aug 2017 B2
9737267 Strom et al. Aug 2017 B2
9743854 Stewart et al. Aug 2017 B2
9763587 Altmann Sep 2017 B2
9763625 Laughner et al. Sep 2017 B2
9782094 Du et al. Oct 2017 B2
9795314 Laughner et al. Oct 2017 B2
9814523 Condie et al. Nov 2017 B2
9848833 Govari et al. Dec 2017 B2
9855421 Garai et al. Jan 2018 B2
9861802 Mickelsen Jan 2018 B2
9875578 Zar et al. Jan 2018 B2
9883908 Madjarov et al. Feb 2018 B2
9895079 Massarwa et al. Feb 2018 B2
9907603 Sklar et al. Mar 2018 B2
9907609 Cao et al. Mar 2018 B2
9913589 Scharf et al. Mar 2018 B2
9918649 Thakur et al. Mar 2018 B2
9918788 Paul et al. Mar 2018 B2
9924994 Sklar et al. Mar 2018 B2
9924995 Sklar et al. Mar 2018 B2
9940747 Katz et al. Apr 2018 B2
9949657 Ravuna et al. Apr 2018 B2
9955889 Urman et al. May 2018 B2
9968783 Bullinga et al. May 2018 B2
9980653 Lichtenstein et al. May 2018 B2
9987083 Gelbart et al. Jun 2018 B2
9987084 Gelbart et al. Jun 2018 B2
10004413 Bokan et al. Jun 2018 B2
10010368 Laske et al. Jul 2018 B2
10016145 Thakur et al. Jul 2018 B2
10028783 Gelbart et al. Jul 2018 B2
10064678 Corvi et al. Sep 2018 B2
10085659 Laughner et al. Oct 2018 B2
20010003158 Kensey et al. Jun 2001 A1
20010005787 Oz et al. Jun 2001 A1
20010018611 Solem et al. Aug 2001 A1
20010020126 Swanson et al. Sep 2001 A1
20010021867 Kordis et al. Sep 2001 A1
20020002329 Avitall Jan 2002 A1
20020016628 Langberg et al. Feb 2002 A1
20020087156 Maguire et al. Jul 2002 A1
20020087157 Sliwa, Jr. et al. Jul 2002 A1
20020087173 Alferness et al. Jul 2002 A1
20020099415 Panescu et al. Jul 2002 A1
20020107478 Wendlandt Aug 2002 A1
20020107511 Collins et al. Aug 2002 A1
20020107530 Saucer et al. Aug 2002 A1
20020115941 Whayne et al. Aug 2002 A1
20020115944 Mendes et al. Aug 2002 A1
20020165535 Lesh et al. Nov 2002 A1
20020169445 Jain et al. Nov 2002 A1
20020169504 Alferness et al. Nov 2002 A1
20020177782 Penner Nov 2002 A1
20020183836 Liddicoat et al. Dec 2002 A1
20020183841 Cohn et al. Dec 2002 A1
20020188170 Santamore et al. Dec 2002 A1
20030028118 Dupree et al. Feb 2003 A1
20030028183 Sanchez et al. Feb 2003 A1
20030050637 Maguire et al. Mar 2003 A1
20030050685 Nikolic et al. Mar 2003 A1
20030055420 Kadhiresan et al. Mar 2003 A1
20030060820 Maguire et al. Mar 2003 A1
20030069570 Witzel et al. Apr 2003 A1
20030069636 Solem et al. Apr 2003 A1
20030078465 Pai et al. Apr 2003 A1
20030078494 Panescu et al. Apr 2003 A1
20030078509 Panescu Apr 2003 A1
20030078671 Lesniak et al. Apr 2003 A1
20030105384 Sharkey et al. Jun 2003 A1
20030105520 Alferness et al. Jun 2003 A1
20030109770 Sharkey et al. Jun 2003 A1
20030125726 Maguire et al. Jul 2003 A1
20030176810 Maahs et al. Sep 2003 A1
20030181819 Desai Sep 2003 A1
20030229395 Cox Dec 2003 A1
20040002626 Feld et al. Jan 2004 A1
20040006337 Nasab et al. Jan 2004 A1
20040054279 Hanley Mar 2004 A1
20040082915 Kadan Apr 2004 A1
20040133220 Lashinski et al. Jul 2004 A1
20040133273 Cox Jul 2004 A1
20040138744 Lashinski et al. Jul 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040158321 Reuter et al. Aug 2004 A1
20040176797 Opolski Sep 2004 A1
20040181139 Falwell et al. Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040193103 Kumar Sep 2004 A1
20040215232 Belhe et al. Oct 2004 A1
20040243170 Suresh et al. Dec 2004 A1
20040249408 Murphy et al. Dec 2004 A1
20040249453 Cartledge et al. Dec 2004 A1
20040267358 Reitan Dec 2004 A1
20050004668 Aklog et al. Jan 2005 A1
20050010206 Nasab et al. Jan 2005 A1
20050015109 Lichtenstein Jan 2005 A1
20050054938 Wehman et al. Mar 2005 A1
20050055089 Macoviak et al. Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050064665 Han Mar 2005 A1
20050065420 Collins et al. Mar 2005 A1
20050065504 Melsky et al. Mar 2005 A1
20050080402 Santamore et al. Apr 2005 A1
20050096047 Haberman et al. May 2005 A1
20050096647 Steinke et al. May 2005 A1
20050107723 Wehman et al. May 2005 A1
20050107871 Realyvasquez et al. May 2005 A1
20050125030 Forsberg et al. Jun 2005 A1
20050148892 Desai Jul 2005 A1
20050149014 Hauck et al. Jul 2005 A1
20050149159 Andreas et al. Jul 2005 A1
20050154252 Sharkey et al. Jul 2005 A1
20050165388 Bhola Jul 2005 A1
20050182365 Hennemann et al. Aug 2005 A1
20050187620 Pai et al. Aug 2005 A1
20050197593 Burbank et al. Sep 2005 A1
20050197692 Pai et al. Sep 2005 A1
20050197693 Pai et al. Sep 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050203558 Maschke Sep 2005 A1
20050209636 Widomski et al. Sep 2005 A1
20050216054 Widomski et al. Sep 2005 A1
20050240249 Tu et al. Oct 2005 A1
20050245892 Elkins Nov 2005 A1
20050251116 Steinke et al. Nov 2005 A1
20050251132 Oral et al. Nov 2005 A1
20050256521 Kozel Nov 2005 A1
20050261580 Willis et al. Nov 2005 A1
20050267458 Paul et al. Dec 2005 A1
20050267463 Vanney Dec 2005 A1
20050267574 Cohn et al. Dec 2005 A1
20060009755 Sra Jan 2006 A1
20060009756 Francischelli et al. Jan 2006 A1
20060014998 Sharkey et al. Jan 2006 A1
20060015002 Moaddeb et al. Jan 2006 A1
20060015003 Moaddes et al. Jan 2006 A1
20060015038 Weymarn-Scharli Jan 2006 A1
20060015096 Hauck et al. Jan 2006 A1
20060025800 Suresh Feb 2006 A1
20060030881 Sharkey et al. Feb 2006 A1
20060084966 Maguire et al. Apr 2006 A1
20060085049 Cory et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060100618 Chan et al. May 2006 A1
20060106298 Ahmed et al. May 2006 A1
20060135968 Schaller Jun 2006 A1
20060135970 Schaller Jun 2006 A1
20060173251 Govari et al. Aug 2006 A1
20060184242 Lichtenstein Aug 2006 A1
20060199995 Vijay Sep 2006 A1
20060229491 Sharkey et al. Oct 2006 A1
20060235286 Stone et al. Oct 2006 A1
20060235314 Migliuolo et al. Oct 2006 A1
20060264980 Khairkhahan et al. Nov 2006 A1
20060281965 Khairkhahan et al. Dec 2006 A1
20060293698 Douk Dec 2006 A1
20060293725 Rubinsky et al. Dec 2006 A1
20070016068 Grunwald et al. Jan 2007 A1
20070027533 Douk Feb 2007 A1
20070038208 Kefer Feb 2007 A1
20070083168 Whiting Apr 2007 A1
20070083193 Werneth et al. Apr 2007 A1
20070083195 Werneth et al. Apr 2007 A1
20070088362 Bonutti et al. Apr 2007 A1
20070115390 Makara et al. May 2007 A1
20070118215 Moaddeb May 2007 A1
20070129717 Brown, III Jun 2007 A1
20070161846 Nikolic et al. Jul 2007 A1
20070198058 Gelbart et al. Aug 2007 A1
20070213578 Khairkhahan et al. Sep 2007 A1
20070213815 Khairkhahan et al. Sep 2007 A1
20070232858 MacNamara et al. Oct 2007 A1
20070249999 Sklar et al. Oct 2007 A1
20070270688 Gelbart et al. Nov 2007 A1
20070299343 Waters Dec 2007 A1
20080004534 Gelbart Jan 2008 A1
20080004643 To et al. Jan 2008 A1
20080004697 Lichtenstein et al. Jan 2008 A1
20080045778 Lichtenstein et al. Feb 2008 A1
20080071298 Khairkhahan et al. Mar 2008 A1
20080161799 Stangenes et al. Jul 2008 A1
20080172048 Martin et al. Jul 2008 A1
20080262337 Falwell et al. Oct 2008 A1
20080281322 Sherman et al. Nov 2008 A1
20080312713 Wilfley et al. Dec 2008 A1
20090018617 Skelton et al. Jan 2009 A1
20090024138 Saleh Jan 2009 A1
20090069704 MacAdam et al. Mar 2009 A1
20090131930 Gelbart et al. May 2009 A1
20090157058 Ferren et al. Jun 2009 A1
20090171274 Harlev et al. Jul 2009 A1
20090182325 Werneth et al. Jul 2009 A1
20090182405 Arnault De La Menardiere Jul 2009 A1
20090192441 Gelbart et al. Jul 2009 A1
20090253976 Harlev et al. Oct 2009 A1
20090270737 Thornton Oct 2009 A1
20090287271 Blum et al. Nov 2009 A1
20090287304 Dahlgren et al. Nov 2009 A1
20100016762 Thapliyal et al. Jan 2010 A1
20100023004 Francischelli et al. Jan 2010 A1
20100113928 Thapliyal et al. May 2010 A1
20100113985 Thapliyal et al. May 2010 A1
20100121147 Oskin et al. May 2010 A1
20100204560 Salahieh Aug 2010 A1
20100211052 Brown et al. Aug 2010 A1
20100249771 Pearson et al. Sep 2010 A1
20100268059 Ryu et al. Oct 2010 A1
20100286551 Harlev et al. Nov 2010 A1
20110034912 De Graff et al. Feb 2011 A1
20110125172 Gelbart et al. May 2011 A1
20110172658 Gelbart et al. Jul 2011 A1
20110213231 Hall et al. Sep 2011 A1
20110282491 Prisco et al. Nov 2011 A1
20120071870 Salahieh Mar 2012 A1
20120078076 Stewart et al. Mar 2012 A1
20120136346 Condie et al. May 2012 A1
20120136348 Condie et al. May 2012 A1
20120158016 Gelbart et al. Jun 2012 A1
20120165829 Chen et al. Jun 2012 A1
20120172859 Condie et al. Jul 2012 A1
20120172867 Ryu et al. Jul 2012 A1
20120271135 Burke et al. Oct 2012 A1
20120277567 Harlev et al. Nov 2012 A1
20130066220 Weinkam et al. Mar 2013 A1
20130165916 Mathur et al. Jun 2013 A1
20130172883 Lopes et al. Jul 2013 A1
20130178850 Lopes et al. Jul 2013 A1
20130178851 Lopes et al. Jul 2013 A1
20130184705 Gelbart et al. Jul 2013 A1
20130184706 Gelbart et al. Jul 2013 A1
20130190587 Lopes et al. Jul 2013 A1
20130190741 Moll et al. Jul 2013 A1
20130197513 Lopes et al. Aug 2013 A1
20130241929 Massarwa et al. Sep 2013 A1
20130274562 Ghaffari et al. Oct 2013 A1
20130296679 Condie et al. Nov 2013 A1
20130296850 Olson Nov 2013 A1
20130304065 Lopes et al. Nov 2013 A1
20130310828 Reinders et al. Nov 2013 A1
20130345538 Harlev et al. Dec 2013 A1
20140114307 Moisa et al. Apr 2014 A1
20140121659 Paul et al. May 2014 A1
20140213894 Gelbart et al. Jul 2014 A1
20140296850 Condie et al. Oct 2014 A1
20140303610 McCarthy et al. Oct 2014 A1
20140303614 McCarthy et al. Oct 2014 A1
20140350552 Highsmith Nov 2014 A1
20140364848 Heimbecher et al. Dec 2014 A1
20150032103 Mclawhorn et al. Jan 2015 A1
20150045660 Gelbart et al. Feb 2015 A1
20150066010 Mclawhorn et al. Mar 2015 A1
20150105701 Mayer et al. Apr 2015 A1
20150126993 Gelbart et al. May 2015 A1
20150157400 Gelbart et al. Jun 2015 A1
20150182740 Mickelsen Jul 2015 A1
20150245798 Gelbart et al. Sep 2015 A1
20150250539 Gelbart et al. Sep 2015 A1
20150351836 Prutchi Dec 2015 A1
20150351837 Gelbart et al. Dec 2015 A1
20150366508 Chou et al. Dec 2015 A1
20160008059 Prutchi Jan 2016 A1
20160008061 Fung et al. Jan 2016 A1
20160008062 Gelbart et al. Jan 2016 A1
20160058505 Condie et al. Mar 2016 A1
20160100884 Fay et al. Apr 2016 A1
20160106498 Highsmith Apr 2016 A1
20160143686 Tunay et al. May 2016 A1
20160175009 Davies et al. Jun 2016 A1
20160242667 Fay et al. Aug 2016 A1
20160262647 Berenfeld Sep 2016 A1
20160287137 Condie et al. Oct 2016 A1
20160302858 Bencini Oct 2016 A1
20160317223 Avitall Nov 2016 A1
20160331259 Harlev et al. Nov 2016 A1
20160346030 Thapliyal et al. Dec 2016 A1
20160361111 Seidel Dec 2016 A1
20160367315 Moisa et al. Dec 2016 A1
20170020604 Lopes et al. Jan 2017 A1
20170027465 Blauer et al. Feb 2017 A1
20170035486 Lopes et al. Feb 2017 A1
20170035499 Stewart et al. Feb 2017 A1
20170065198 Ruppersberg Mar 2017 A1
20170065339 Mickelsen Mar 2017 A1
20170065340 Long Mar 2017 A1
20170065812 Goedeke et al. Mar 2017 A1
20170071661 Hoitink et al. Mar 2017 A1
20170079712 Levin et al. Mar 2017 A1
20170092013 Perlman et al. Mar 2017 A1
20170100189 Clark et al. Apr 2017 A1
20170103570 Zar et al. Apr 2017 A1
20170105627 Katz et al. Apr 2017 A1
20170119453 Ryu et al. May 2017 A1
20170143414 Sliwa et al. May 2017 A1
20170156791 Govari Jun 2017 A1
20170156792 Ziv-Ari et al. Jun 2017 A1
20170164858 Basu Jun 2017 A1
20170202470 Urman et al. Jul 2017 A1
20170202516 Bar-Tal et al. Jul 2017 A1
20170202521 Urman et al. Jul 2017 A1
20170215947 Rioux et al. Aug 2017 A1
20170281193 Asirvatham et al. Oct 2017 A1
20170296084 Blauer et al. Oct 2017 A1
20170312012 Harlev et al. Nov 2017 A1
20170312028 Harlev et al. Nov 2017 A1
20170333124 Gelbart et al. Nov 2017 A1
20180008343 Gelbart et al. Jan 2018 A1
20180020916 Ruppersberg Jan 2018 A1
20180036074 Gelbart et al. Feb 2018 A1
20180036076 Gelbart et al. Feb 2018 A1
20180036077 Gelbart et al. Feb 2018 A1
20180042667 Pappone et al. Feb 2018 A1
20180042671 Gelbart et al. Feb 2018 A1
20180042674 Mickelsen Feb 2018 A1
20180042675 Long Feb 2018 A1
20180055565 Gelbart et al. Mar 2018 A1
20180056074 Clark et al. Mar 2018 A1
20180064488 Long et al. Mar 2018 A1
20180068439 Hareland Mar 2018 A1
20180071017 Bar-Tal et al. Mar 2018 A1
20180092688 Tegg Apr 2018 A1
20180093088 Mickelsen Apr 2018 A1
20180110561 Levin et al. Apr 2018 A1
20180116595 Ruppersberg May 2018 A1
20180117304 Koop et al. May 2018 A1
20180125575 Schwartz et al. May 2018 A1
20180153437 Schwartz et al. Jun 2018 A1
20180158238 Cohen et al. Jun 2018 A1
20180160978 Cohen et al. Jun 2018 A1
20180161097 Zoabi et al. Jun 2018 A1
20180177467 Katz et al. Jun 2018 A1
20180177552 Zoabi et al. Jun 2018 A1
20180182157 Zar et al. Jun 2018 A1
20180182159 Cohen et al. Jun 2018 A1
20180190009 Cohen et al. Jul 2018 A1
20180199976 Fischer Jul 2018 A1
20180199990 Monir et al. Jul 2018 A1
20180200497 Mickelsen Jul 2018 A1
20180206920 Pappone et al. Jul 2018 A1
20180214202 Howard et al. Aug 2018 A1
20180235692 Efimov et al. Aug 2018 A1
20180236221 Opie et al. Aug 2018 A1
20180242868 Cohen et al. Aug 2018 A1
20180256055 Zigelman et al. Sep 2018 A1
20180280070 Pasquino et al. Oct 2018 A1
20180296114 Welsh et al. Oct 2018 A1
20180325597 Schwartz et al. Nov 2018 A1
20190046265 Moisa et al. Feb 2019 A1
20190223950 Gelbart Jul 2019 A1
20190239948 Gelbart Aug 2019 A1
20190307506 Gelbart Oct 2019 A1
20190343570 Lopes Nov 2019 A1
20190365449 Lopes Dec 2019 A1
20190380760 Lopes Dec 2019 A1
20200046425 Lopes Feb 2020 A1
20200054394 Gelbart Feb 2020 A1
20200375659 Gelbart Dec 2020 A1
20210000537 Gelbart Jan 2021 A1
20210059750 Gelbart Mar 2021 A1
20210169544 Lopes Jun 2021 A1
Foreign Referenced Citations (91)
Number Date Country
101797181 Aug 2010 CN
102010026210 Jan 2012 DE
102011085720 May 2013 DE
0723467 Jul 1996 EP
1169974 Jan 2002 EP
1169976 Jan 2002 EP
1240868 Sep 2002 EP
1182980 Jun 2006 EP
1233718 Aug 2006 EP
1923095 May 2008 EP
1280467 Nov 2008 EP
1451595 Jul 2009 EP
1814450 Jan 2013 EP
1909679 Nov 2013 EP
2101642 Jul 2014 EP
2307098 Mar 2015 EP
2848191 Mar 2015 EP
2231060 May 2015 EP
2873365 May 2015 EP
2984986 Feb 2016 EP
2395933 May 2016 EP
2645953 Aug 2016 EP
2661236 Aug 2016 EP
2749213 Sep 2016 EP
2604211 Oct 2016 EP
3130285 Feb 2017 EP
3141185 Mar 2017 EP
2689722 Jun 2017 EP
2566565 Oct 2017 EP
2613723 Oct 2017 EP
3225161 Oct 2017 EP
2892454 Jan 2018 EP
3318211 May 2018 EP
3321890 May 2018 EP
3102136 Jun 2018 EP
2765939 Sep 2018 EP
2793725 Sep 2018 EP
3139997 Sep 2018 EP
3375365 Sep 2018 EP
9510320 Apr 1995 WO
9520349 Aug 1995 WO
9717892 May 1997 WO
0108575 Feb 2001 WO
02087437 Nov 2002 WO
03015611 Feb 2003 WO
03077800 Sep 2003 WO
2004012629 Feb 2004 WO
2004047679 Jun 2004 WO
2004084746 Oct 2004 WO
2004100803 Nov 2004 WO
2005070330 Aug 2005 WO
2005102181 Nov 2005 WO
2006017809 Feb 2006 WO
2006105121 Oct 2006 WO
2006135747 Dec 2006 WO
2006135749 Dec 2006 WO
2007021647 Feb 2007 WO
2007115390 Oct 2007 WO
2008002606 Jan 2008 WO
2009011721 Jan 2009 WO
2009065042 May 2009 WO
2012050877 Apr 2012 WO
2012100184 Jul 2012 WO
2012100185 Jul 2012 WO
2013064576 May 2013 WO
2013173917 Nov 2013 WO
2016181316 Nov 2016 WO
2016181317 Nov 2016 WO
2016181318 Nov 2016 WO
2016183468 Nov 2016 WO
2017009165 Jan 2017 WO
2017024123 Feb 2017 WO
2017041889 Mar 2017 WO
2017041891 Mar 2017 WO
2017042623 Mar 2017 WO
2017056056 Apr 2017 WO
2017070252 Apr 2017 WO
2017087740 May 2017 WO
2017120169 Jul 2017 WO
2017136262 Aug 2017 WO
2017192480 Nov 2017 WO
2017192495 Nov 2017 WO
2017192510 Nov 2017 WO
2017192542 Nov 2017 WO
2018023132 Feb 2018 WO
2018067540 Apr 2018 WO
2018075396 Apr 2018 WO
2018081225 May 2018 WO
2018144765 Aug 2018 WO
2018146613 Aug 2018 WO
2018165425 Sep 2018 WO
Non-Patent Literature Citations (274)
Entry
Examination Report issued in European Appln. No. 14871405.8 dated Jul. 6, 2018.
Notice of Allowance issued in U.S. Appl. No. 13/785,910 dated Jun. 15, 2018.
Buchbinder, Maurice Md, “Dynamic Mitral Valve Annuloplasty: A Reshapable Ring for Residual and Recurring MR,” from the Foundation for Cardiovascular Medicine, La Jolla, CA. May 24, 2007.
Gabriel et al., “The Dielectric Properties of Biological Tissues: I. Literature Survey,” Phys. Med. Biol. 41:2231-2249, 1996.
Konings et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries,” IEEE Transactions on Medical Imaging, 16(4):439-446, 1997.
Mack, “New Techniques for Percutaneous Repair of the Mitral Valve,” Heart Failure Review, 11:259-268, 2006.
Otasevic et al., “First-in-Man Implantation of Left Ventricular Partitioning Device in a Patient With Chronic Heart Failure: Twelve-Month Follow-up,” Journal of Cardiac Failure 13(7):517-520, 2007.
Sharkey et al., “Left Ventricular Apex Occluder. Description of a Ventricular Partitioning Device,” EuroIntervention 2:125-127, 2006.
Stiles, et al., “Simulated Characterization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance,” IEE Transactions on Biomedical Engineering, 50(7):916-921,2003.
Tanaka et al., “Artificial SMA Valve for Treatment of Urinary Incontinence: Upgrading of Valve and Introduction of Transcutaneous Transformer,” Bio-Medical Materials and Engineering 9:97-112, 1999.
Timek et al.., “Septal-Lateral Annular Cinching (‘SLAC’) Reduces Mitral Annular Size Without Perturbing Normal Annular Dynamics,” Journal of Heart Valve Disease 11 (1):2-10, 2002.
Timek et al., “Septal-Lateral Annular Cinching Abolishes Acute Ischemic Mitral Regurgitation,” Journal of Thoracic and Cardiovascular Surgery, 123(5):881-888, 2002.
Valvano et al., “Thermal Conductivity and Diffusivity of Biomaterials Measured with Self-Heated Thermistors,” International Journal of Thermodynamics, 6(3):301-311, 1985.
Gelbart et al., “Automatic Atherectomy System,” Office Action dated Mar. 4, 2009 for U.S. Appl. No. 11/436,584, 7 pages.
Gelbart et al., “Automatic Atherectomy System,” Amendment filed Aug. 4, 2009 for U.S. Appl. No. 11/436,584, 35 pages.
Gelbart et al., “Automatic Atherectomy System,” Office Action dated Dec. 1, 2009 for U.S. Appl. No. 11/436,584, 10 pages.
Gelbart et al., “Automatic Atherectomy System,” Amendment filed Mar. 30, 2010 for U.S. Appl. No. 11/436,584, 20 pages.
Gelbart et al., “Automatic Atherectomy System,” Amendment filed Oct. 25, 2010 for U.S. Appl. No. 11/436,584, 9 pages.
Gelbart et al., “Automatic Atherectomy System,” Office Action dated Dec. 14, 2010 for U.S. Appl. No. 11/436,584, 12 pages.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method,” Preliminary Amendment filed Aug. 29, 2007 for U.S. Appl. No. 11/475,950,42 pages.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method,” Amendment filed Mar. 5, 2008 for U.S. Appl. No. 11/475,950, 11 pages.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method,” Office Action dated Jun. 23, 2010 for U.S. Appl. No. 11/475,950, 18 pages.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method,” Amendment filed Aug. 16, 2010 for U.S. Appl. No. 11/475,950, 22 pages.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method,” Office Action dated Nov. 23, 2010 for U.S. Appl. No. 11/475,950, 25 pages.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method,” Amendment filed Feb. 23, 2011 for U.S. Appl. No. 11/475,950, 28 pages.
Gelbart et al., “Automatic Atherectomy System,” Office Action dated Jun. 15, 2011, for U.S. Appl. No. 12/950,871, 16 pages.
Gelbart et al., “Liposuction System,” Office Action dated Mar. 16, 2011 for U.S. Appl. No. 12/010,458, 12 pages.
Gelbart et al., “Liposuction System,” Amendment filed Jun. 10, 2011 for U.S. Appl. No. 12/010,458, 10 pages.
Lightenstein “Method and Apparatus for Percutaneous Reduction of Anterior-Posterior Diameter of Mitral Valve,” U.S. Appl. No. 10/690,131, filed Oct. 20, 2003, 31 pages.
International Search Report, dated Dec. 5, 2007, for PCT/US2007/014902, 5 pages.
International Preliminary Report on Patentability, dated Jan. 6, 2009, for PCT/US2007/014902, 8 pages.
International Search Report, dated Dec. 2, 2009, for PCT/US2008/083644, 5 pages.
Written Opinion, dated Dec. 5, 2007, for PCT/US2007/014902, 7 pages.
Written Opinion, dated Dec. 2, 2009, for PCT/US2008/083644, 9 pages.
Gelbart et al., “Automatic Atherectomy System,” Amendment filed Sep. 15, 2011 for U.S. Appl. No. 12/950,871, 21 pages.
Gelbart et al., “Liposuction System,” Amendment filed Dec. 7, 2011 for U.S. Appl. No. 12/010,458, 15 pages.
Gelbart et al., “Liposuction System,” Office Action dated Sep. 14, 2011 for U.S. Appl. No. 12/010,458, 9 pages.
Notice of Allowance issued in U.S. Appl. No. 13/782,889, dated Aug. 25, 2016.
Office Action issued in U.S. Appl. No. 15/697,744 dated Feb. 28, 2020.
Office Action issued in U.S. Appl. No. 15/784,647 dated Feb. 28, 2020.
Office Action issued in U.S. Appl. No. 15/784,555 dated Mar. 9, 2020.
Examination Report issued in Indian Application No. 9902/DELNP/2014 dated Jun. 19, 2020. English translation provided.
Office Action issued in U.S. Appl. No. 15/697,744 dated Jul. 8, 2020.
Amendment and Statement on the Substance of the Interview filed in U.S. Appl. No. 15/784,722 dated Jul. 9, 2020.
Amendment and Statement on the Substance of the Interview filed in U.S. Appl. No. 15/784,775 dated Jul. 9, 2020.
Notice of Allowance issued in U.S. Appl. No. 15/784,647 dated Jul. 23, 2020.
Becker R. et al., “Ablation of Atrial Fibrillation: Energy Sources and Navigation Tools: A Review”, Journal of Electrocardiology, 37 (Supplement 2004): 55-62, 2004.
Calkins, Hugh, “Radiofrequency Catheter Ablation of Supraventricular Arrhythmias”, Heart, 85:594-600, 2001.
De Ponti et al., “Non-Fluoroscopic Mapping Systems for Electrophysiology: The ‘Tool or Toy’ Dilemma After 10 Years”,European Heart Journal 27:1134-1136, 2006.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Office Action dated Dec. 13, 2013; Notice of Allowance dated Jul. 25, 2014 for U.S. Appl. No. 11/475,950, 19 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Office Action dated Jan. 3, 2012; Office Action dated Apr. 3, 2014; Notice of Allowance dated Aug. 26, 2014 for U.S. Appl. No. 11/941,819, 35 pgs.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Amendment filed Apr. 10, 2014 Supplemental Amendment filed Feb. 12, 2013 for U.S. Appl. No. 11/475,950, 21 pgs.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Preliminary Amendment filed Aug. 22, 2014; Preliminary Amendment filed Mar. 5, 2013 for U.S. Appl. No. 13/785,910, 10 pgs.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Preliminary Amendment filed Aug. 22, 2014; Preliminary Amendment filed Mar. 5, 2013 for U.S. Appl. No. 13/785,931, 10 pgs.
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Preliminary Amendment filed Oct. 22, 2013 for U.S. Appl. No. 13/942,354, 13 pgs.
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Preliminary Amendment filed Aug. 20, 2014 for U.S. Appl. No. 13/782,889, 11 pgs.
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Preliminary Amendment filed Mar. 14, 2013 for U.S. Appl. No. 13/782,867, 8 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Amendment filed Jul. 3, 2014; Amendment filed Apr. 2, 2012; Amendment filed Mar. 1, 2012; Amendment filed Nov. 23, 2011; Replacement drawings filed Feb. 13, 2008 for U.S. Appl. No. 11/941,819, 78 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Preliminary Amendment filed May 12, 2014; Preliminary Amendment filed May 2, 2014 for U.S. Appl. No. 14/229,305, 12 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Preliminary Amendment filed May 12, 2014; Preliminary Amendment filed May 2, 2014 for U.S. Appl. No. 14/229,250, 10 pgs.
Gelbart et al., Medical Device for Use in Bodily Lumens, for Example an Atrium, Amendment filed Sep. 22, 2014, for U.S. Appl. No. 13/070,215, 18 pgs.
Gelbart et al., Medical Device for Use in Bodily Lumens, for Example an Atrium, Office Action dated Jun. 20, 2014, for U.S. Appl. No. 13/070,215, 8 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Supplemental Notice of Allowance dated Oct. 6, 2014 for U.S. Appl. No. 11/941,819, 4 pgs.
Notice of Allowance issued in U.S. Appl. No. 13/793,213 dated Aug. 10, 2016.
Non-Final Office Action issued in U.S. Appl. No. 13/942,354 dated Aug. 4, 2016.
Notice of Allowance issued in U.S. Appl. No. 14/136,946 dated May 12, 2016.
Notice of Allowance issued in U.S. Appl. No. 13/782,867 dated Aug. 12, 2016.
Notice of Allowance issued in U.S. Appl. No. 13/782,903 dated Jul. 6, 2016.
Corrected Notice of Allowance issued in U.S. Appl. No. 13/782,903 dated Jul. 19, 2016.
Non-Final Office Action issued in U.S. Appl. No. 14/229,305, dated Apr. 29, 2016.
Notice of Allowance issued in U.S. Appl. No. 29/509,621, dated Sep. 27, 2016.
Notice of Allowance issued in U.S. Appl. No. 29/509,636, dated Sep. 27, 2016.
Extended European Search Report issued in European Application No. 19189222.3 dated Nov. 29, 2019.
Notice of Intention to Grant issued in EP Appln. No. 14871405.8 dated Jan. 22, 2019.
Notice of Intention to Grant issued in EP Appln. No. 15188407.9 dated Mar. 20, 2019.
Second Preliminary Amendment filed in copending U.S. Appl. No. 16/521,745 dated Aug. 15, 2019.
Notice of Allowance issued in U.S. Appl. No. 15/254,130 dated Sep. 12, 2019.
Second Preliminary Amendment filed in copending U.S. Appl. No. 16/521,732 dated Aug. 15, 2019.
Preliminary Amendment filed in copending U.S. Appl. No. 16/369,528 dated Apr. 24, 2019.
Preliminary Amendment filed in U.S. Appl. No. 16/381,317 dated Apr. 24, 2019.
Preliminary Amendment filed in copending U.S. Appl. No. 16/381,344 dated Apr. 24, 2019.
Preliminary Amendment filed in U.S. Appl. No. 15/784,647 dated Nov. 7, 2017.
Notice of Allowance issued in U.S. Appl. No. 15/663,077 dated Sep. 24, 2019.
Preliminary Amendment filed in U.S. Appl. No. 16/407,379 dated Jun. 12, 2019.
Office Action issued in U.S. Appl. No. 15/254,130 dated May 28, 2019.
Preliminary Amendment filed in copending U.S. Appl. No. 16/521,745 dated Jul. 25, 2019.
Notice of Intention to Grant issued in EP Appln. No. 13793216.6 dated Jul. 15, 2019.
Extended European Search Report issued in European Appln. No. 19172980.5 dated Aug. 21, 2019.
Second Preliminary Amendment filed in copending U.S. Appl. No. 16/521,712 dated Aug. 15, 2019.
Amendment filed in U.S. Appl. No. 15/254,130 dated Aug. 13, 2019.
Preliminary Amendment filed in copending U.S. Appl. No. 16/521,712 dated Jul. 25, 2019.
Preliminary Amendment filed in copending U.S. Appl. No. 16/521,732 dated Jul. 25, 2019.
Office Action issued in U.S. Appl. No. 15/784,722 dated Mar. 23, 2020.
Office Action issued in U.S. Appl. No. 15/784,775 dated Mar. 23, 2020.
Amendment filed in U.S. Appl. No. 14/804,924 dated Feb. 27, 2018.
Amendment filed in U.S. Appl. No. 14/804,810 dated Feb. 27, 2018.
Notice of Allowance issued in U.S. Appl. No. 14/804,924 dated Mar. 27, 2018.
Notice of Allowance issued in U.S. Appl. No. 14/804,810 dated Mar. 30, 2018.
Office Action issued in Chinese Application No. 201510432392.3 dated May 18, 2018. Concise Explanation of Relevance provided.
Office Action issued in U.S. Appl. No. 13/785,910 dated Jan. 12, 2018.
Amendment filed in U.S. Appl. No. 13/785,910 dated Feb. 27, 2018.
Amendment filed in U.S. Appl. No. 14/564,463 dated Oct. 17, 2017.
Notice of Allowance issued in U.S. Appl. No. 14/713,114 dated Nov. 1, 2017.
Notice of Allowance issued in U.S. Appl. No. 14/564,463 dated Nov. 9, 2017.
Preliminary Amendment filed in U.S. Appl. No. 15/784,775 dated Nov. 7, 2017.
Preliminary Amendment filed in U.S. Appl. No. 15/784,722 dated Nov. 7, 2017.
Preliminary Amendment filed in U.S. Appl. No. 15/725,731 dated Oct. 24, 2017.
Preliminary Amendment filed in U.S. Appl. No. 15/784,555 dated Nov. 7, 2017.
Preliminary Amendment filed in U.S. Appl. No. 15/725,662 dated Oct. 24, 2017.
Office Action issued in U.S. Appl. No. 14/804,924 dated Nov. 17, 2017.
Response to Office Action filed in U.S. Appl. No. 13/785,910 dated Nov. 30, 2017.
Office Action issued in U.S. Appl. No. 14/804,810 dated Nov. 30, 2017.
Examination Report issued in European Application No. 13793216.6 dated Nov. 24, 2017.
Office Action issued in Chinese Application No. 201510432392.3 dated Nov. 17, 2017. English translation provided.
Examination Report issued in European Application No. 15188407.9 dated Dec. 11, 2017.
Response to Examination Opinion filed Mar. 18, 2021 for Chinese Patent Application No. 201810941271.5.
Office Action issued in copending U.S. Appl. No. 15/287,988 dated May 5, 2021.
Office Action issued in Chinese Patent Application No. 201810941271.5 dated Jun. 3, 2021. English language Statemenl of Relevance provided.
Amendment filed in copending U.S. Appl. No. 15/287,988 dated Jul. 28, 2021.
Non-Final Office Action issued in copending U.S. Appl. No. 16/521,712 dated Sep. 30, 2021.
Lopes et al., “Intra-Cardiac Procedure Device”, Amendment filed in U.S. Appl. No. 29/509,636 filed on Jul. 22, 2016, 5 pgs.
Lopes et al., “Intra-Cardiac Procedure Device”, Amendment filed in U.S. Appl. No. 29/509,636 dated Nov. 17, 2016, 3 pgs.
Lopes et al., “High-Density Electrode-Based Medical Device System”, Preliminary Amendment filed in U.S. Appl. No. 15/287,988 dated Nov. 23, 2016, 9 pgs.
Lopes et al., “Intra-Cardiac Procedure Device”, Amendment filed in U.S. Appl. No. 29/509,621 dated Jul. 22, 2016, 5 pgs.
Lopes et al., “Intra-Cardiac Procedure Device”, Amendment filed in U.S. Appl. No. 29/509,621 dated Nov. 17, 2016, 3 pgs.
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Amendment filed in U.S. Appl. No. 13/782,889 dated May 17, 2016, 51 pgs.
Lopes et al., “High-Density Electrode-Based Medical Device System” Amendment filed in U.S. Appl. No. 13/793,213 dated May 26, 2016, 39 pgs.
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Amendment filed in U.S. Appl. No. 13/782,867 dated May 17, 2016, 39 pgs.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Amendment filed in U.S. Appl. No. 11/475,950 dated Feb. 12, 2013, 4 pgs.
Moisa et al., “Catheter System”, Preliminary Amendment filed in U.S. Appl. No. 15/254,130 dated Sep. 19, 2016, 22 pgs.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Preliminary Amendment filed in U.S. Appl. No. 14/804,924 dated Jul. 30, 2015, 5 pgs.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Preliminary Amendment filed in U.S. Appl. No. 14/804,810 dated Jul. 30, 2015, 10 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Preliminary Amendment filed in U.S. Appl. No. 14/713,190 dated May 15, 2015, 3 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Preliminary Amendment filed in U.S. Appl. No. 14/713,190 dated Jun. 16, 2015, 7 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Preliminary Amendment filed in U.S. Appl. No. 14/713,114 dated Jun. 16, 2015, 8 pgs.
Office Action issued in U.S. Appl. No. 14/521,692 dated Jan. 10, 2017.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Amendment filed in U.S. Appl. No. 14/229,305 dated Sep. 27, 2016, 15 pgs.
Notice of Allowance issued in U.S. Appl. No. 14/229,305 dated Nov. 8, 2016.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Amendment filed in U.S. Appl. No. 14/229,250 dated Sep. 27, 2016, 13 pgs.
Notice of Allowance issued in U.S. Appl. No. 14/229,250 dated Dec. 7, 2016.
Moisa et al., “Catheter System”, Amendment filed in U.S. Appl. No. 14/136,946 dated Apr. 18, 2016, 19 pgs.
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Amendment filed in U.S. Appl. No. 13/942,354 dated Jan. 4, 2017, 23 pgs.
Lopes et al., “High-Density Electrode-Based Medical Device System”, Preliminary Amendment filed in U.S. Appl. No. 13/793,076 dated May 26, 2016, 15 pgs.
Lopes et al., “High-Density Electrode-Based Medical Device System”, Amendment filed in U.S. Appl. No. 13/793,076 dated May 9, 2016, 15 pgs.
Gelbart et al., “Apparatus and Method for Intracardiac Mapping and Ablation”, Preliminary Amendment filed in U.S. Appl. No. 13/785,931 dated Mar. 5, 2013, 2 pgs.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Amendment filed in U.S. Appl. No. 13/785,910 dated Feb. 9, 2016, 11 pgs.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Amendment filed in U.S. Appl. No. 13/785,910 dated Jan. 5, 2016, 15 pgs.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Amendment filed in U.S. Appl. No. 13/785,910 dated Aug. 8, 2016, 18 pgs.
Office Action issued in U.S. Appl. No. 13/785,910 dated Nov. 2, 2016.
Bard, “Mesh Ablator Catheter”, Brochure, 2008, 4 pgs, Bard Electrophysiology Division, C.R. Bard Inc., 55 Technology Drive Lowell, MA 07851 USA.
Biotronik'S “AlCath Flutter Gold Cath for Atrial Flutter Available in EU”, Sep. 19, 2013, medGadget, 3 pgs, http://www.medgadget.com/2013/09/biotroniks-alcath-flutter-gold-cath-for-atrial-flutter-unveiled-in-europe.html [Jun. 24, 2014 2:37:09 PM].
“Constellation Mapping Catheters”, Brochure, Boston Scientific Corp., 2 pgs © 2007 Boston Scientific Corporation.
“Waveforms and Segments”, Ensite System Instructions for use, 54-06154-001 Rev02, Chapter 7 pages 85-90 © 2007 St. Jude Medical.
Extended European Search Report and EP search opinion for EP 12736677.1, dated Mar. 28, 2014, corresponding to PCT/US2012/022061.
Extended European Search Report and EP search opinion for EP 12736962.7, dated Mar. 28, 2014, corresponding to PCT/US2012/022062.
Extended European Search Report dated Aug. 20, 2013 issued in EP Patent Application No. 13172848.7.
Written Opinion dated Aug. 22, 2012 for PCT/US2012/022061, 6 pgs.
International Search Report and Written Opinion dated Aug. 2, 2013 issued in PCT/CA2013/050350.
International Search Report and Written Opinion dated Sep. 17, 2013 issued in PCT/US2013/039982.
International Search Report and Written Opinion dated Sep. 27, 2013 issued in PCT/US2013/039977.
International Search Report dated Jul. 30, 2012 for PCT/US2012/022062, 5 pgs.
Written Opinion dated Jul. 30, 2012 for PCT/US2012/022062, 5 pgs.
International Search Report dated Aug. 22, 2012 for PCT/US2012/022061, 5 pgs.
“Phased RF Catheter Ablation System”, 2014 Medtronic Inc., 2 pgs, http://www.medtronic.eu/your-health/atrial-fibrillation/about-the-therapy/our-phased-rf-ablation-system/[Jun. 24, 2014 2:38:05 PM].
“ThermoCool® Irrigated Tip Catheter”, Brochure, Biosense Webster, 4 pgs , Biosense Webster, Inc. 3333 Diamond Canyon Road Diamond Bar, CA 91765, USA, © Biosense Webster, Inc. 2009 All rights reserved. 1109003.0.
Gelbart “Medical Device for Use in Bodily Lumens, for Example an Atrium”, OA dated Jul. 25, 2011 tor U.S. Appl. No. 11/941,819, now published as US 2009-0131930 A1.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Notice of Allowance dated Oct. 23, 2014 for U.S. Appl. No. 11/475,950, 10 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Notice of Allowance dated Nov. 13, 2014 for U.S. Appl. No. 13/070,215, 54 pages.
International Search Report dated Mar. 10, 2015, for International Application PCT/CA2014/051144; 10 pages.
Written Opinion dated Mar. 10, 2015, for International Application PCT/CA2014/051144; 4 pages.
Official Action issued in CN201280004400.9, dated Dec. 3, 2014.
Non-Final Office Action issued in U.S. Appl. No. 13/782,867, dated Apr. 15, 2015.
Non-Final Office Action issued in U.S. Appl. No. 13/782,903, dated Apr. 28, 2015.
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Office Action dated May 22, 2015 for U.S. Appl. No. 13/782,889, 86 pages.
Lopes et al., “High-Density Electrode-Based Medical Device System”, Office Action dated Jul. 10, 2015 for U.S. Appl. No. 13/793,076, 98 pages.
Lopes et al., “High-Density Electrode-Based Medical Device System”, Office Action dated Jul. 9, 2015 tor U.S. Appl. No. 13/793,213, 99 pages.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Office Action dated Aug. 5, 2015 for U.S. Appl. No. 13/785,910, 79 pages.
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Amendment filed Aug. 24, 2015 for U.S. Appl. No. 13/782,889, 21 pages.
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Amendment filed Aug. 28, 2015 for U.S. Appl. No. 13/782,903, 19 pages.
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Amendment filed Sep. 14, 2015 for U.S. Appl. No. 13/782,867, 25 pages.
Lopes et al., “High-Density Electrode-Based Medical Device System ”, Amendment filed Oct. 9, 2015 for U.S. Appl. No. 13/793,213, 26 pages.
Lopes et al., “High-Density Electrode-Based Medical Device System ”, Amendment filed Oct. 9, 2015 for U.S. Appl. No. 13/793,076, 14 pages.
Examination Report issued in EP13172848.7, dated Sep. 21, 2015.
Extended European Search Report issued in EP13793216.6, dated Oct. 30, 2015.
Moisa et al., “Catheter System”, Office Action dated Nov. 16, 2015 for U.S. Appl. No. 14/136,946, 92 pages.
Office Action issued in U.S. Appl. No. 13/782,889, dated Dec. 18, 2015.
Office Action issued in U.S. Appl. No. 13/782,903, dated Dec. 18, 2015.
Extended European Search Report issued in EP15188407.9, dated Jan. 21, 2016.
Lopes et al. “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Office Action dated Jan. 25, 2016 for U.S. Appl. No. 13/782,867, 49 pages.
Notice of Allowance issued in U.S. Appl. No. 13/793,076, dated Feb. 10, 2016.
Final Office Action issued in U.S. Appl. No. 13/793,213, dated Feb. 26, 2016.
Non-Final Office Action issued in U.S. Appl. No. 29/509,719, dated Feb. 25, 2016.
Quayle issued in U.S. Appl. No. 29/509,621, dated Feb. 26, 2016.
Quayle issued in U.S. Appl. No. 29/509,636, dated Feb. 26, 2016.
Non-Final Office Action issued in U.S. Appl. No. 13/785,910 dated Apr. 8, 2016.
Non-Final Office Action issued in U.S. Appl. No. 14/229,250 dated Apr. 28, 2016.
Notice of Allowance issued in U.S. Appl. No. 13/793,076 dated Jul. 7, 2016.
Extended European Search Report issued in European Application No. 19215957.2 dated Mar. 26, 2020.
Office Action issued in copending U.S. Appl. No. 16/658,820 dated Oct. 22, 2021.
Copending U.S. Appl. No. 17/513,070, filed Oct. 28, 2021.
Office Action issued in copending U.S. Appl. No. 16/662,537 dated Oct. 29, 2021.
Amendment filed in copending U.S. Appl. No. 16/521,712 dated Nov. 1, 2021.
Preliminary Amendment filed in copending U.S. Appl. No. 17/513,070 dated Nov. 8, 2021.
Notice of Allowance issued in copending U.S. Appl. No. 15/287,988 dated Nov. 15, 2021.
Office Action issued in copending U.S. Appl. No. 15/299,640 dated Nov. 12, 2021.
Office Action issued in U.S. Appl. No. 15/725,662 dated May 13, 2020.
Office Action issued in U.S. Appl. No. 15/725,731 dated May 15, 2020.
Amendment filed in U.S. Appl. No. 15/784,647 dated May 27, 2020.
Amendment filed in U.S. Appl. No. 15/697,744 dated May 27, 2020.
Amendment filed in U.S. Appl. No. 15/784,555 dated Jun. 3, 2020.
Notice of Allowance issued in U.S. Appl. No. 15/784,775 dated Aug. 7, 2020.
Notice of Allowance issued in U.S. Appl. No. 15/784,555 dated Aug. 11, 2020.
Amendment and Statement on the Substance of the Interview filed in U.S. Appl. No. 15/725,662 dated Aug. 13, 2020.
Amendment and Statement on the Substance of the Interview filed in U.S. Appl. No. 15/725,731 dated Aug. 13, 2020.
Notice of Allowance issued in U.S. Appl. No. 15/784,722 dated Aug. 14, 2020.
Office Action issued in U.S. Appl. No. 16/407,379 dated Dec. 24, 2020.
Amendment filed in U.S. Appl. No. 16/407,379 dated Mar. 23, 2021.
Notice of Allowance issued in U.S. Appl. No. 15/725,662 dated Sep. 3, 2020.
Notice of Allowance issued in U.S. Appl. No. 15/725,731 dated Sep. 3, 2020.
Notice of Allowance issued in U.S. Appl. No. 15/697,744 dated Sep. 18, 2020.
Preliminary Amendment filed in copending U.S. Appl. No. 16/995,159 dated Sep. 25, 2020.
Preliminary Amendment filed in copending U.S. Appl. No. 16/995,222 dated Sep. 25, 2020.
Preliminary Amendment filed in copending U.S. Appl. No. 17/182,732 dated Mar. 11, 2021.
Preliminary Amendment filed in copending U.S. Appl. No. 17/072,262 dated Dec. 1, 2020.
Office Action issued in Chinese Appln. No. 201810941271.5 dated Nov. 3, 2020. English translation provided.
Preliminary Amendment filed in copending U.S. Appl. No. 17/182,732 dated Feb. 23, 2021.
Notice of Allowance issued in U.S. Appl. No. 16/407,379 dated Apr. 1, 2021.
Office Action issued in German Patent Appln. No. 112008003108.8 dated Oct. 28, 2019. English machine translation provided.
Preliminary Amendment filed in copending U.S. Appl. No. 16/662,537 dated Nov. 19, 2019.
Preliminary Amendment filed in copending U.S. Appl. No. 16/655,775 dated Nov. 1, 2019.
Office Action issued in U.S. Appl. No. 14/564,463 dated Feb. 28, 2017.
Notice of Allowance issued in U.S. Appl. No. 13/942,354 dated Feb. 10, 2017.
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Amendment filed in co-pending U.S. Appl. No. 13/785,910 dated Mar. 24, 2017, 30 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Amendment filed in co-pending U.S. Appl. No. 14/521,692 dated Mar. 31, 2017, 9 pgs.
Office Action issued in Chinese Patent Application No. 201510432392.3 dated Mar. 8, 2017. English concise Explanation of Relevance provided.
Decision to Refuse a European Patent Application issued in European Patent Application No. 13172848.7 dated Feb. 22, 2017.
Notice of Allowance issued in U.S. Appl. No. 14/521,692 dated May 19, 2017.
Office Action issued in U.S. Appl. No. 14/713,114 dated Jun. 1, 2017.
Quayle Action issued in U.S. Appl. No. 14/713,190 dated May 30, 2017.
Office Action issued in German Application No. 112008003108.8 dated May 8, 2017. English translation provided.
Amendment filed in U.S. Appl. No. 14/564,463, filed May 25, 2017.
Office Action issued in U.S. Appl. No. 14/564,463 dated Jul. 17, 2017.
European Search Report issued in European Appln. No. 14871405.8 dated Jul. 5, 2017.
Preliminary Amendment filed in U.S. Appl. No. 15/299,640 pp. 4 filed Oct. 21, 2016.
Preliminary Amendment filed in U.S. Appl. No. 15/299,640 pp. 11 filed Dec. 9, 2016.
Response to Quayle Office Action filed in U.S. Appl. No. 14/713,190, filed Jul. 24, 2017.
Preliminary Amendment filed in U.S. Appl. No. 14/521,692, filed Oct. 23, 2014.
Preliminary Amendment filed in U.S. Appl. No. 15/697,744 dated Sep. 21, 2017.
Preliminary Amendment filed in U.S. Appl. No. 15/663,077 dated Aug. 8, 2017.
Amendment filed in U.S. Appl. No. 14/713,114, filed Aug. 23, 2017.
Notice of Allowance issued in U.S. Appl. No. 14/713,190 dated Aug. 28, 2017.
Office Action issued in U.S. Appl. No. 13/785,910 dated Aug. 30, 2017.
Amendment filed in copending U.S. Appl. No. 16/381,317 dated Apr. 4, 2022.
Notice of Allowance issued in copending U.S. Appl. No. 16/658,820 dated Mar. 11, 2022.
Amendment filed in copending U.S. Appl. No. 16/369,528 dated Mar. 2, 2022.
Amendment filed in copending U.S. Appl. No. 16/381,344 dated Apr. 4, 2022.
Depending U.S. Appl. No. 17/716,303, filed Apr. 8, 2022.
Supplemental Amendment filed in copending U.S. Appl. No. 15/299,640 dated Mar. 1, 2022.
Non-Final Office Action issued in copending U.S. Appl. No. 17/584,705 dated Mar. 29, 2022.
Office Action issued in copending European Application No. 19172980.5 dated Jan. 21, 2022.
Amendment filed in copending U.S. Appl. No. 15/299,640 dated Feb. 8, 2022.
Notice of Allowance issued in copending U.S. Appl. No. 16/662,537 dated Feb. 14, 2022.
Notice of Allowance issued in copending U.S. Appl. No. 16/161,319 dated Feb. 16, 2022.
Non-Final Office Action issued in copending U.S. Appl. No. 16/369,528 dated Dec. 6, 2021.
Notice of Allowance issued in Chinese Application No. 201810941271.5 dated Dec. 22, 2021.
Non-Final Office Action issued in copending U.S. Appl. No. 16/381,317 dated Jan. 10, 2022.
Notice of Allowance issued in copending U.S. Appl. No. 16/521,712 dated Jan. 11, 2022.
Amendment filed in copending U.S. Appl. No. 16/658,820 dated Jan. 17, 2022.
Amendment filed in copending U.S. Appl. No. 16/662,537 dated Jan. 18, 2022.
Non-Final Office Action issued in copending U.S. Appl. No. 16/381,344 dated Feb. 1, 2022.
Preliminary Amendment filed in copending U.S. Appl. No. 17/584,705 dated Feb. 2, 2022.
Notice of Allowance issued in copending U.S. Appl. No. 16/369,528 dated May 12, 2022.
Notice of Allowance issued in copending U.S. Appl. No. 16/381,317 dated May 16, 2022.
Notice of Allowance issued in copending U.S. Appl. No. 16/381,344 dated May 16, 2022.
Related Publications (1)
Number Date Country
20220031391 A1 Feb 2022 US
Continuations (6)
Number Date Country
Parent 16658820 Oct 2019 US
Child 17500186 US
Parent 15784647 Oct 2017 US
Child 16658820 US
Parent 14713190 May 2015 US
Child 15784647 US
Parent 14564463 Dec 2014 US
Child 14713190 US
Parent 13070215 Mar 2011 US
Child 14564463 US
Parent 11941819 Nov 2007 US
Child 13070215 US